{"gene":"TFPI","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1988,"finding":"LACI (later renamed TFPI) directly inhibits factor Xa at or near its active site, and in a factor Xa-dependent manner inhibits the factor VIIa/tissue factor (TF) complex, consistent with formation of a quaternary VIIa-TF-Xa-LACI complex. The gamma-carboxyglutamic acid (Gla) domain of factor Xa is required for this quaternary complex formation and for efficient TF/VIIa inhibition.","method":"In vitro chromogenic substrate assay, nondenaturing PAGE complex detection, Gla-domain-deleted factor Xa competition experiments, antibody inhibition studies","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with multiple orthogonal methods; foundational mechanistic study replicated across labs","pmids":["3422166"],"is_preprint":false},{"year":1988,"finding":"LACI/TFPI is encoded by a cDNA predicting a 276-residue mature protein with three tandem Kunitz-type serine protease inhibitory domains, a negatively charged N-terminus, and a positively charged C-terminus, with multiple molecular weight forms in plasma associated with apolipoprotein A-II via mixed disulfide bonds.","method":"cDNA cloning, nucleotide sequencing, Northern blot, 125I-factor Xa binding assay, lambda gt11 library screening with polyclonal antiserum","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — cDNA sequence with direct protein validation and functional binding assay; foundational structural discovery","pmids":["2452157"],"is_preprint":false},{"year":1987,"finding":"Inhibition of TF activity by the extrinsic pathway inhibitor (EPI/TFPI) requires the simultaneous presence of factor VIIa/TF, factor Xa (with active site intact), calcium, and EPI; the inhibition is reversible and factor VIIa/TF activity can be recovered from a dissociated inhibited complex. Preliminary incubation of EPI with factor Xa alone or factor VIIa/TF alone does not substitute for simultaneous presence of all components.","method":"Activated peptide release assay using 3H-factor IX substrate, plasma reconstitution experiments with purified/depleted components, EPI supplementation and antibody blocking","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — multiple reconstitution experiments with defined components; replicated in subsequent studies","pmids":["3492226"],"is_preprint":false},{"year":1987,"finding":"The TF inhibitory activity present in serum (later identified as TFPI) requires factor VII(a), catalytically active factor Xa, and an additional plasma component present in BaSO4-absorbed serum. HepG2 hepatoma cells secrete this inhibitory activity in vitro, identifying endothelium/liver as a source of TFPI.","method":"Clotting assay using crude TF with immunodepleted and BaSO4-absorbed plasma fractions; HepG2 conditioned media assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple plasma-fractionation approaches, cell culture validation; foundational identification of TFPI activity","pmids":["3024756"],"is_preprint":false},{"year":1989,"finding":"Site-directed mutagenesis of each of the three Kunitz domains of LACI/TFPI revealed that Kunitz domain 2 (K2) is required for efficient binding and inhibition of factor Xa, and that both K1 and K2 are required for inhibition of VIIa/TF; K3 active-site mutation has no significant effect on either function. This established the domain-function map: K1 binds VIIa/TF active site, K2 binds Xa active site.","method":"Site-directed mutagenesis of active-site residues in each Kunitz domain, followed by functional assays for Xa inhibition and VIIa/TF inhibition in vitro","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct active-site mutagenesis with quantitative functional readout; foundational domain mapping study","pmids":["2927510"],"is_preprint":false},{"year":1989,"finding":"Plasma LACI/TFPI was purified and shown to exist in multiple molecular weight forms (40–130 kDa); the 46-kDa and larger forms are associated with apolipoprotein A-II via mixed disulfide linkages. LDL contains primarily the 40-kDa form while HDL contains primarily the LACI/apoA-II complex form, with ~50% of plasma TFPI associated with LDL/VLDL.","method":"Sequential hydrophobic, ion-exchange, and affinity chromatography purification; SDS-PAGE; N-terminal sequencing; lipoprotein fractionation; gel filtration","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — protein purification with biochemical characterization; lipoprotein association directly demonstrated","pmids":["2553722"],"is_preprint":false},{"year":1988,"finding":"Heparin induces release of EPI (TFPI) from endothelial cells into the circulation in a dose-dependent manner following intravenous injection, an effect not abolished by polybrene or anti-antithrombin antibodies, suggesting active secretion from endothelial stores rather than antithrombin displacement. Gel filtration of endothelial cell culture supernatant reveals a single inhibitory fraction at ~43 kDa.","method":"Chromogenic substrate assay for EPI activity in plasma; in vivo heparin injection in humans; gel filtration of endothelial cell conditioned medium; polybrene neutralization and antibody blocking controls","journal":"Thrombosis research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (in vitro cell culture + in vivo human pharmacology + antibody controls); replicated in subsequent studies","pmids":["3413731"],"is_preprint":false},{"year":1990,"finding":"TFPI (LACI) acts as a cofactor for heparin in inhibiting tissue factor-induced coagulation: in LACI-depleted plasma, heparin causes only moderate linear prolongation of prothrombin time, while normal plasma shows greater and threshold-dependent anticoagulation at the same heparin concentrations, demonstrating synergistic anticoagulant action between LACI and sulfated polysaccharides.","method":"APTT and modified prothrombin time assays with LACI-depleted plasma reconstituted with purified recombinant LACI; titration with unfractionated heparin and various sulfated polysaccharides","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of depleted plasma with purified recombinant protein; dose-response characterization; replicated finding","pmids":["1346095"],"is_preprint":false},{"year":1990,"finding":"TFPI regulates tissue factor-induced coagulation as a multivalent Kunitz-type inhibitor, directly inhibiting activated factor X and producing feedback inhibition of the factor VIIa/tissue factor catalytic complex in a factor Xa-dependent manner.","method":"Biochemical reconstitution, enzyme kinetics, plasma coagulation assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — mechanistic reconstitution study; foundational description of TFPI as a multivalent inhibitor","pmids":["2271516"],"is_preprint":false},{"year":1991,"finding":"EPI (TFPI) is released into blood during extensive physical exercise (30 km cross-country skiing or long-distance running), with peak plasma EPI levels reached 2 hours post-exercise, suggesting mobilization from endothelial stores and possibly from lipoprotein-associated pools due to exercise-induced lipoprotein lipase activity.","method":"EPI plasma activity assay in athletes before and after exercise of various durations; plasma volume-corrected measurements","journal":"Thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 3 — single in vivo observational study measuring TFPI release; no direct mechanistic dissection","pmids":["2274917"],"is_preprint":false},{"year":1991,"finding":"EPI (TFPI) released in vivo by heparin significantly contributes to the post-heparin anticoagulant effect (prolonged clotting time and retarded fibrinopeptide A release) as demonstrated by blocking with polyclonal anti-EPI antibodies in post-heparin plasma, including plasma from cancer patients.","method":"Polybrene neutralization of heparin followed by TTP/CaCl2-triggered coagulation; polyclonal blocking antibody addition; clotting time and fibrinopeptide A release assay","journal":"Thrombosis research supplement","confidence":"Medium","confidence_rationale":"Tier 2 — blocking antibody approach demonstrates functional contribution of TFPI to post-heparin anticoagulation","pmids":["1658969"],"is_preprint":false},{"year":1993,"finding":"TFPI is a major anticoagulant in normal plasma specifically in the extrinsic (tissue factor) pathway, with its effect particularly pronounced at prolonged clotting times and enhanced by the simultaneous presence of other anticoagulants (heparin/antithrombin); blocking TFPI in warfarin-treated plasma significantly shortens clotting times. The TFPI/antithrombin cooperation is dependent on antithrombin anticoagulant activity.","method":"APTT and PT clotting assays with TFPI-depleted plasma, TFPI/heparin/hirudin combinations, ATIII-deficient plasma, warfarin-treated plasma; polyclonal antibody depletion","journal":"Thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 — systematic plasma depletion/reconstitution experiments defining TFPI's quantitative contribution to anticoagulation","pmids":["8259547"],"is_preprint":false},{"year":2001,"finding":"TFPI structure comprises three Kunitz domains with defined functions: K1 inhibits factor VIIa complexed to tissue factor, K2 inhibits factor Xa, and K3 has no demonstrated direct protease-inhibiting function. The C-terminal basic region is required for rapid physiological inhibition of coagulation and for inhibition of smooth muscle cell proliferation, and plays an important role in cell surface binding.","method":"Structural analysis, domain-deletion studies, cell proliferation assays, binding studies reviewed from multiple primary sources","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 1 — synthesis of mutagenesis, structural, and cell-based experiments from multiple independent studies","pmids":["11686353"],"is_preprint":false},{"year":2006,"finding":"Protein S stimulates inhibition of factor Xa by full-length TFPI approximately 10-fold by reducing the Ki of the FXa/TFPI complex from 4.4 nM to 0.5 nM. This cofactor activity of protein S is specific to full-length TFPI (not truncated forms) and brings TFPI inhibitory concentration into the physiologically relevant plasma range, demonstrating that protein S and TFPI act together to inhibit TF activity.","method":"Purified protein reconstitution with chromogenic substrate assay for FXa inhibition; kinetic analysis (Ki determination); thrombin generation assays in plasma","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — quantitative kinetic reconstitution with purified proteins; Ki measured directly; supported by plasma thrombin generation assays","pmids":["16488980"],"is_preprint":false},{"year":2009,"finding":"Full-length TFPI and protein S form a complex in plasma as demonstrated by protein S immunodepletion experiments and surface plasmon resonance, which reduces full-length TFPI levels in hereditary and acquired protein S deficiency. The co-deficiency of TFPI substantially contributes to the hypercoagulable state associated with protein S deficiency.","method":"Plasma immunodepletion of protein S, TFPI antigen measurement by ELISA, surface plasmon resonance binding analysis, thrombin generation by calibrated automated thrombography","journal":"Journal of thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding confirmed by SPR; functional consequence shown by thrombin generation; protein S depletion/normalization experiments","pmids":["20002538"],"is_preprint":false},{"year":2013,"finding":"Direct inhibition of TF-bound FVIIa by full-length TFPI requires contributions from multiple domains: K2 alone is a poor TF-FVIIa inhibitor (Ki=434 nM); K1-K2 improves this; the K3-C-terminus further enhances FVIIa inhibition (~7–10-fold) though is not essential for quaternary TF-FVIIa-TFPI-FXa complex formation. In the quaternary complex, Ki values drop to <0.15 nM for full-length TFPI. Phospholipids and the Gla-domain of FXa are required for quaternary complex formation. Protein S further stimulates TF-FVIIa inhibition by full-length TFPI.","method":"Chromogenic substrate assay for FVIIa activity; truncated TFPI constructs (KD1, KD1-KD2, TFPI1-150, full-length); relipidated and soluble TF; kinetic analysis; protein S and phospholipid titrations","journal":"Journal of thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 1 — systematic domain-deletion analysis with quantitative kinetics; multiple orthogonal construct comparisons","pmids":["23347185"],"is_preprint":false},{"year":2013,"finding":"TFPIα produces isoform-specific rapid inhibition of prothrombinase (FXa/FVa/phospholipid/Ca2+ complex) during coagulation initiation, mediated through a high-affinity exosite interaction between the basic C-terminus of TFPIα and an acidic region in the factor V/Va B domain retained in FXa-activated and platelet-derived FVa. This inhibitory activity is absent in TFPIβ and is lost after thrombin cleaves the acidic region from FVa.","method":"Purified prothrombinase reconstitution assays; TFPIα/TFPIβ isoform comparison; factor Va B-domain acidic region deletion mutants; platelet-derived FVa testing; thrombin cleavage experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstitution, mutagenesis, isoform comparison, and mechanistic dissection in a single study; novel anticoagulant function established","pmids":["24127605"],"is_preprint":false},{"year":2014,"finding":"TFPIα and TFPIβ are alternatively spliced isoforms with distinct expression patterns and anticoagulant activities: TFPIα is the only isoform in platelets, while endothelial cells produce both isoforms (secreting TFPIα and expressing TFPIβ on the cell surface via GPI anchor). TFPIβ is a potent surface inhibitor of TF-FVIIa on endothelial cells; TFPIα contains a unique basic C-terminus that interacts with factor V B domain to inhibit prothrombinase during coagulation initiation.","method":"Isoform characterization via alternative splicing analysis; cell-type expression studies; GPI anchor validation; platelet vs. endothelial cell functional comparison; review of primary reconstitution data","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — synthesis of multiple primary mechanistic studies defining isoform-specific biochemistry and localization","pmids":["24620349"],"is_preprint":false},{"year":2015,"finding":"Physiological concentrations of phospholipids (~10 µM negatively charged) enhance FXa inhibition by full-length TFPI 5–6-fold. Unfractionated heparin at 0.2–1 U/ml enhances FXa inhibition ~8-fold but impairs inhibition at >1 U/ml. Protein S and factor V (but not thrombin-activated FVa) each enhance FXa inhibition 2–3-fold, while FVa impairs TFPI-mediated FXa inhibition. TFPI fails to inhibit FXa-catalyzed prothrombin activation in the presence of FVa (prothrombinase). These modulatory effects are absent for truncated TFPI1-150, identifying the K3-C-terminus as essential for exosite-mediated regulation.","method":"Progress curve analysis with chromogenic substrate CS11-(65); systematic titration of phospholipids, heparin, prothrombin, FV, FVa, protein S; full-length vs. truncated TFPI comparison","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 1 — systematic quantitative kinetics with purified components; multiple modulators tested; structural domain attribution via truncation","pmids":["26607136"],"is_preprint":false},{"year":2014,"finding":"TFPI selectively inhibits MASP-2 of the lectin pathway of complement without affecting MASP-1, C1s, or C1r, thus acting as an inhibitor of complement activation. The Kunitz-2 domain of TFPI is required for MASP-2 inhibition. This was demonstrated using rTFPI, MASP-2 chromogenic assay, C4-deposition assay, and domain-specific blocking monoclonal antibodies.","method":"Ex vivo lectin pathway activation on mannan-coated plates (C4 deposition assay); fluid-phase MASP-2 chromogenic assay; domain-specific anti-TFPI monoclonal antibodies to map K2 requirement","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional assay with domain mapping via blocking antibodies; single lab but multiple complementary assays","pmids":["25359215"],"is_preprint":false},{"year":2010,"finding":"Surface TFPI on human monocytes acts as an important regulator of monocyte procoagulant reactivity: pre-incubation of LPS-stimulated PBMCs with anti-TFPI IgG significantly enhanced TF activity, shortened lag-time, and increased thrombin generation. LPS stimulation causes parallel upregulation of both TFPIα and TFPIβ mRNA isoforms on monocyte surfaces, where TFPI co-localizes with TF.","method":"RT-qPCR for TFPI mRNA isoforms; flow cytometry and confocal microscopy for surface presentation; TF activity assay; calibrated automated thrombogram (CAT); anti-TFPI IgG blocking","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blocking with functional readout; co-localization; isoform quantification; single lab","pmids":["20723970"],"is_preprint":false},{"year":2015,"finding":"A balance between TFPI anticoagulant activity and thrombin-mediated platelet activation via PAR4 is required for murine embryonic development. PAR4 deficiency (but not PAR3 deficiency) partially rescues >40% of Tfpi-null (Tfpi−/−) embryos from lethal disseminated intravascular coagulation, demonstrating that TFPI physiologically modulates thrombin-dependent platelet activation in vivo. Adult Tfpi−/−:Par4−/− mice show focal liver fibrin deposition and elevated thrombin-antithrombin complexes, indicating that TFPI dampens intravascular procoagulant stimuli even without thrombin-mediated platelet activation.","method":"Genetic epistasis (Tfpi+/−:Par4−/− crosses); survival analysis; immunohistochemistry for fibrin(ogen); plasma thrombin-antithrombin complex measurement; venous electrolytic injury model; TF-induced pulmonary embolism model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (double knockout rescue) with multiple in vivo phenotypic readouts; defines TFPI-PAR4 functional axis","pmids":["25954015"],"is_preprint":false},{"year":2016,"finding":"Conditional knockout of TFPI-1 in vascular smooth muscle cells (VSMCs) of ApoE−/− mice accelerates atherosclerosis with increased VSMC proliferation and migration. By mass spectrometry, immunoprecipitation, and co-localization, TFPI-1 was found to interact with angiomotin (AMOT) in human VSMCs. TFPI-1 deficiency decreases AMOT and YAP phosphorylation, leading to increased expression of SLUG and CTGF (Hippo pathway targets linked to atherosclerosis).","method":"Conditional knockout mouse model (Tfpi1fl/fl/Sma-Cre+ApoE−/−); Sudan IV staining; immunohistochemistry; mass spectrometry identification of AMOT as binding partner; Co-IP and co-localization; Western blot for AMOT/YAP phosphorylation; qPCR for target genes","journal":"International journal of cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with in vivo phenotype + Co-IP/MS identification of AMOT interaction + signaling pathway changes; single lab","pmids":["27875740"],"is_preprint":false},{"year":2003,"finding":"Low TFPI and low antithrombin levels in neonates (~50% of adult values) act synergistically to allow sufficient thrombin generation at low tissue factor concentrations, explaining the clinically excellent hemostasis of neonates despite reduced procoagulant factors. At <10 pmol/L lipidated TF, cord plasma clots faster and generates more free thrombin (~90% of adult value) than adult plasma due to combined low TFPI and antithrombin.","method":"In vitro clotting assay with lipidated TF titration; factor Xa generation and thrombin generation assays in neonatal cord plasma vs. adult plasma; TFPI and antithrombin concentration measurements","journal":"Journal of thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 — functional plasma reconstitution experiments demonstrating TFPI's quantitative contribution to neonatal hemostasis","pmids":["12871499"],"is_preprint":false},{"year":2010,"finding":"Transgenic expression of TFPI on porcine aortic endothelial cells (PAECs) inhibits TF activity induced by anti-nonGal IgG binding via a complement-independent pathway, effectively preventing coagulation dysregulation in a xenotransplantation model. Atorvastatin or anti-IgG Fab antibody similarly inhibits TF expression.","method":"PAEC culture from wild-type, GT-KO, CD46-transgenic, and TFPI-transgenic pigs; TF activity assay; incubation with naive and sensitized baboon serum; heat inactivation and antibody blocking controls","journal":"Journal of thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic cell expression with functional TF activity assay; defined mechanistic context","pmids":["20553382"],"is_preprint":false},{"year":2022,"finding":"TFPI is identified as the colonic crypt receptor for TcdB variants (TcdB2 and TcdB4) from hypervirulent clade 2 Clostridioides difficile. CRISPR/Cas9 genome-wide screens identified TFPI as the receptor for TcdB4. Cryo-EM structure of full-length TcdB4 in complex with TFPI defined the receptor-binding region. TFPI is highly expressed in intestinal glands, and recombinant TFPI protects the colonic epithelium from TcdB2/4 toxin.","method":"CRISPR/Cas9 genome-wide loss-of-function screen; cryo-EM structure determination of TcdB4-TFPI complex; TFPI expression analysis in intestinal tissue; recombinant TFPI protection assay of colonic epithelium","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — CRISPR screen + cryo-EM structure + functional protection assay; multiple orthogonal methods in single study","pmids":["35303428"],"is_preprint":false},{"year":2022,"finding":"TFPI serves as a host receptor for multiple TcdB subtypes (TcdB2, 4, 7, 10, 11, 12) from C. difficile that do not recognize Frizzled proteins. A six-residue haplotype within the TcdB receptor-binding region distinguishes TFPI-binding (B4/B7 haplotype) from FZD-binding TcdB variants. Intragenic micro-recombination events drive receptor-specificity switching. TcdB10 recognizes chicken/mouse TFPI but not human TFPI, revealing species selectivity. Introduction of B4/B7-haplotype residues into TcdB1 enables dual recognition of TFPI and FZDs.","method":"CRISPR-Cas9 genome-wide screen; receptor binding assays across TcdB subtypes; sequence analysis of 206 TcdB variants; site-directed mutagenesis of receptor-binding residues; species-selectivity binding assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — CRISPR screen + mutagenesis + cross-species binding assays; replicates and extends PMID 35303428 finding","pmids":["36351897"],"is_preprint":false},{"year":2016,"finding":"A C-terminal peptide (TC24) derived from fish (Cynoglossus semilaevis) TFPI-1 exhibits bactericidal activity against multiple bacterial species (S. aureus, V. vulnificus, M. luteus) by penetrating bacterial cell membranes and inducing degradation of genomic DNA and total RNA. In vivo administration of TC24 reduces pathogen dissemination and viral replication in tongue sole tissues.","method":"Antimicrobial assay; membrane integrity assay; intracellular localization by microscopy; genomic DNA/RNA degradation assay; in vivo challenge with bacteria and virus followed by pathogen quantification in tissues","journal":"Fish & shellfish immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro mechanistic assays (membrane disruption, nucleic acid degradation) plus in vivo protection; fish ortholog of TFPI","pmids":["27840169"],"is_preprint":false}],"current_model":"TFPI is a multivalent Kunitz-type plasma anticoagulant that directly inhibits factor Xa via its K2 domain, and in a factor Xa-dependent manner forms a quaternary inhibitory complex (TF-FVIIa-FXa-TFPI) to shut down extrinsic pathway initiation, with K1 engaging the FVIIa active site; protein S acts as a cofactor reducing the Ki for FXa inhibition ~10-fold; the TFPIα isoform additionally inhibits prothrombinase through a novel exosite interaction between its basic C-terminus and the factor Va B-domain acidic region; TFPIβ is GPI-anchored to endothelial surfaces; heparin releases TFPI from endothelial stores; TFPI also inhibits MASP-2 of the lectin complement pathway via K2; interacts with angiomotin (AMOT) in vascular smooth muscle cells to modulate YAP/Hippo signaling; and its extracellular domains serve as the colonic crypt receptor for clade 2 C. difficile TcdB toxin variants."},"narrative":{"teleology":[{"year":1987,"claim":"Establishing that tissue factor pathway inhibition requires the simultaneous presence of factor VIIa/TF, catalytically active FXa, and the inhibitor resolved the long-standing question of how the extrinsic pathway is downregulated by showing it depends on its own product (FXa) as a cofactor for feedback inhibition.","evidence":"Reconstituted activated peptide release assays using purified/depleted plasma components with 3H-FIX substrate","pmids":["3492226","3024756"],"confidence":"High","gaps":["Molecular identity of the inhibitor was not yet determined","Stoichiometry of the quaternary complex was unknown"]},{"year":1988,"claim":"Cloning TFPI (LACI) revealed a three-Kunitz-domain architecture and demonstrated that it directly inhibits FXa and forms a quaternary VIIa–TF–Xa–LACI complex requiring the FXa Gla domain, providing the first molecular framework for its dual inhibitory mechanism.","evidence":"cDNA cloning and sequencing; in vitro chromogenic substrate assays, nondenaturing PAGE complex detection, Gla-domain-deleted FXa competition","pmids":["2452157","3422166"],"confidence":"High","gaps":["Which Kunitz domain inhibits which protease was unknown","Post-translational processing and isoform diversity were uncharacterized"]},{"year":1988,"claim":"Demonstrating that heparin releases TFPI from endothelial cells in a dose-dependent manner identified the vascular endothelium as a physiological reservoir and suggested that part of heparin's clinical anticoagulant effect operates through TFPI mobilization.","evidence":"In vivo heparin injection in humans; chromogenic EPI activity assay in plasma; gel filtration of endothelial conditioned medium; polybrene/antibody controls","pmids":["3413731"],"confidence":"High","gaps":["Mechanism of endothelial TFPI storage and release was undefined","Relative contributions of heparin-released TFPI vs. antithrombin potentiation were not quantified"]},{"year":1989,"claim":"Site-directed mutagenesis mapped K2 as the FXa-inhibitory domain and K1 as the VIIa/TF-inhibitory domain, while K3 had no direct protease-inhibiting function, establishing the domain-function architecture that guided all subsequent TFPI biology.","evidence":"Active-site mutagenesis of each Kunitz domain with quantitative FXa and VIIa/TF inhibition assays","pmids":["2927510"],"confidence":"High","gaps":["Function of K3 and the C-terminal basic region remained unknown","Structural basis of the K1–VIIa and K2–Xa interactions was unresolved"]},{"year":1990,"claim":"Reconstitution experiments in TFPI-depleted plasma demonstrated that TFPI synergizes with heparin/sulfated polysaccharides to prolong tissue factor-triggered clotting, quantifying TFPI as a physiologically significant modulator of the anticoagulant effect of heparin therapy.","evidence":"APTT and modified PT assays with LACI-depleted plasma reconstituted with purified recombinant LACI; heparin and polysaccharide titrations","pmids":["1346095","2271516"],"confidence":"High","gaps":["Whether TFPI acts additively or mechanistically synergistically with antithrombin was unclear","In vivo quantitative contribution of TFPI to heparin anticoagulation was not yet established"]},{"year":2006,"claim":"Identification of protein S as a cofactor that reduces the TFPI–FXa Ki ~10-fold (from 4.4 nM to 0.5 nM) answered the question of how TFPI achieves effective FXa inhibition at its low plasma concentration, revealing a previously unrecognized anticoagulant partnership.","evidence":"Purified protein reconstitution with chromogenic substrate assay; kinetic Ki determination; plasma thrombin generation assays","pmids":["16488980"],"confidence":"High","gaps":["Binding interface between protein S and TFPI was not structurally defined","Whether protein S cofactor activity is isoform-specific was unknown"]},{"year":2009,"claim":"Demonstration that protein S and TFPI form a stable plasma complex — and that protein S deficiency causes co-depletion of TFPI — established that the hypercoagulable state in protein S deficiency is partly attributable to loss of TFPI function.","evidence":"Protein S immunodepletion with TFPI ELISA quantification; surface plasmon resonance binding; calibrated automated thrombography","pmids":["20002538"],"confidence":"High","gaps":["Stoichiometry and domain requirements for the protein S–TFPI complex were not mapped","Clinical impact of co-deficiency versus isolated protein S deficiency was not dissected"]},{"year":2013,"claim":"Discovery that TFPIα inhibits prothrombinase through a high-affinity exosite interaction between its basic C-terminus and the FVa B-domain acidic region — lost after thrombin cleaves FVa — revealed an entirely new anticoagulant function beyond TF pathway inhibition, providing a temporal switch that limits early but not propagated coagulation.","evidence":"Purified prothrombinase reconstitution; TFPIα vs. TFPIβ comparison; FVa B-domain deletion mutants; thrombin cleavage experiments","pmids":["24127605"],"confidence":"High","gaps":["Structural basis of the C-terminus–B-domain interaction was not resolved","Physiological contribution of prothrombinase inhibition versus TF pathway inhibition in vivo was unmeasured"]},{"year":2013,"claim":"Systematic domain-deletion kinetics showed that the K3–C-terminal region enhances FVIIa inhibition 7–10-fold and that phospholipids and the FXa Gla domain are essential for quaternary complex assembly, completing the quantitative model of TFPI's multidomain inhibitory mechanism.","evidence":"Chromogenic FVIIa activity assays with truncated TFPI constructs; relipidated and soluble TF; protein S titrations; quantitative Ki analysis","pmids":["23347185"],"confidence":"High","gaps":["Atomic-resolution structure of the full quaternary complex was not available","How membrane composition modulates complex assembly in vivo was unclear"]},{"year":2014,"claim":"Showing that TFPI selectively inhibits MASP-2 (but not MASP-1, C1s, or C1r) via K2 expanded TFPI's functional repertoire beyond coagulation to regulation of the lectin complement pathway, suggesting a role at the coagulation–innate immunity interface.","evidence":"Lectin pathway C4 deposition assay on mannan-coated plates; fluid-phase MASP-2 chromogenic assay; domain-mapping with anti-K2 monoclonal antibodies","pmids":["25359215"],"confidence":"Medium","gaps":["In vivo significance of TFPI–MASP-2 inhibition for complement regulation was not demonstrated","Whether physiological TFPI concentrations are sufficient to modulate lectin pathway in plasma was untested"]},{"year":2015,"claim":"Genetic epistasis showing that PAR4 deficiency partially rescues Tfpi-null embryonic lethality demonstrated that TFPI's physiological role extends to modulating thrombin-dependent platelet activation in vivo, and that loss of TFPI causes lethal disseminated intravascular coagulation through uncontrolled thrombin signaling.","evidence":"Tfpi−/−:Par4−/− double knockout mouse crosses; survival analysis; fibrin immunohistochemistry; thrombin-antithrombin complex measurement; injury models","pmids":["25954015"],"confidence":"High","gaps":["Whether TFPIα prothrombinase inhibition specifically mediates the embryonic rescue was not dissected","Human genetic correlates of TFPI deficiency remain poorly defined"]},{"year":2016,"claim":"Conditional TFPI knockout in vascular smooth muscle cells accelerated atherosclerosis and identified angiomotin (AMOT) as a TFPI-interacting partner that modulates YAP/Hippo signaling, revealing a non-hemostatic function of TFPI in vascular remodeling.","evidence":"Conditional knockout mouse (Tfpi1fl/fl/Sma-Cre+ApoE−/−); mass spectrometry; Co-IP of AMOT; Western blot for YAP phosphorylation; qPCR for SLUG/CTGF","pmids":["27875740"],"confidence":"Medium","gaps":["Direct binding interface between TFPI and AMOT was not mapped","Whether AMOT interaction is isoform-specific was not determined","Single lab without independent replication"]},{"year":2022,"claim":"Identification of TFPI as the colonic crypt receptor for clade 2 C. difficile TcdB variants — supported by CRISPR screening, cryo-EM structure, and functional protection assays — established an unexpected role for TFPI's extracellular domains in toxin entry and defined a new therapeutic target for hypervirulent C. difficile infection.","evidence":"Genome-wide CRISPR/Cas9 screen; cryo-EM of TcdB4–TFPI complex; recombinant TFPI protection of colonic epithelium; cross-subtype binding and mutagenesis across 206 TcdB variants","pmids":["35303428","36351897"],"confidence":"High","gaps":["Whether TFPI-mediated toxin entry occurs via endocytosis of the GPI-anchored TFPIβ isoform or free TFPIα was not resolved","Species selectivity determinants on TFPI itself were not fully mapped"]},{"year":null,"claim":"Key unresolved questions include the atomic-resolution structure of the full quaternary TF–FVIIa–FXa–TFPI complex, the structural basis of the TFPIα C-terminus interaction with the FVa B-domain, in vivo quantification of the relative contributions of TFPIα prothrombinase inhibition versus TF pathway inhibition, and the physiological significance of TFPI–MASP-2 inhibition in complement regulation.","evidence":"","pmids":[],"confidence":"Low","gaps":["Full quaternary complex structure unavailable","In vivo dissection of isoform-specific anticoagulant contributions incomplete","Physiological relevance of complement pathway inhibition by TFPI untested in animal models"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2,4,8,13,15,16,18]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[4,8]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,5,6,9,13,14]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[17,20]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0,2,4,7,8,11,13,15,16,17,18,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[22]}],"complexes":["TF-FVIIa-FXa-TFPI quaternary complex","TFPI-protein S complex","FXa-FVa prothrombinase (TFPIα target)"],"partners":["F10","F7","F3","PROS1","F5","MASP2","AMOT"],"other_free_text":[]},"mechanistic_narrative":"TFPI is a multivalent Kunitz-type serine protease inhibitor that serves as the primary physiological regulator of the extrinsic coagulation pathway by directly inhibiting factor Xa through its Kunitz-2 (K2) domain and, in a factor Xa-dependent manner, forming a quaternary TF–FVIIa–FXa–TFPI complex in which K1 engages the FVIIa active site to shut down tissue factor-initiated coagulation [PMID:3422166, PMID:2927510, PMID:2271516]. Protein S acts as a cofactor that enhances TFPI-mediated FXa inhibition approximately 10-fold, bringing the Ki into the physiologically relevant range, while the TFPIα isoform additionally inhibits prothrombinase through an exosite interaction between its basic C-terminus and the factor Va B-domain acidic region — an activity lost upon thrombin cleavage of FVa — whereas TFPIβ is GPI-anchored to endothelial surfaces where it directly inhibits TF–FVIIa [PMID:16488980, PMID:24127605, PMID:24620349]. Beyond hemostasis, TFPI inhibits MASP-2 of the lectin complement pathway via K2 [PMID:25359215], interacts with angiomotin in vascular smooth muscle cells to modulate YAP/Hippo signaling and suppress atherosclerotic remodeling [PMID:27875740], and functions as the colonic crypt receptor for clade 2 Clostridioides difficile TcdB toxin variants as defined by CRISPR screening and cryo-EM structural analysis [PMID:35303428, PMID:36351897]."},"prefetch_data":{"uniprot":{"accession":"P10646","full_name":"Tissue factor pathway inhibitor","aliases":["Extrinsic pathway inhibitor","EPI","Lipoprotein-associated coagulation inhibitor","LACI"],"length_aa":304,"mass_kda":35.0,"function":"Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma","subcellular_location":"Microsome membrane","url":"https://www.uniprot.org/uniprotkb/P10646/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TFPI","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TFPI","total_profiled":1310},"omim":[{"mim_id":"614489","title":"MICRO RNA 616; MIR616","url":"https://www.omim.org/entry/614489"},{"mim_id":"614348","title":"ANDROGEN-DEPENDENT TFPI-REGULATING PROTEIN; ADTRP","url":"https://www.omim.org/entry/614348"},{"mim_id":"613878","title":"COAGULATION FACTOR VII; F7","url":"https://www.omim.org/entry/613878"},{"mim_id":"600033","title":"TISSUE FACTOR PATHWAY INHIBITOR 2; TFPI2","url":"https://www.omim.org/entry/600033"},{"mim_id":"152310","title":"TISSUE FACTOR PATHWAY INHIBITOR; TFPI","url":"https://www.omim.org/entry/152310"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":254.3},{"tissue":"placenta","ntpm":179.5}],"url":"https://www.proteinatlas.org/search/TFPI"},"hgnc":{"alias_symbol":["EPI","TFI","TFPI1"],"prev_symbol":["LACI"]},"alphafold":{"accession":"P10646","domains":[{"cath_id":"4.10.410.10","chopping":"47-119","consensus_level":"medium","plddt":85.7521,"start":47,"end":119},{"cath_id":"4.10.410.10","chopping":"122-179","consensus_level":"medium","plddt":91.6634,"start":122,"end":179},{"cath_id":"4.10.410.10","chopping":"216-269","consensus_level":"high","plddt":92.2165,"start":216,"end":269}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10646","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10646-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10646-F1-predicted_aligned_error_v6.png","plddt_mean":73.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TFPI","jax_strain_url":"https://www.jax.org/strain/search?query=TFPI"},"sequence":{"accession":"P10646","fasta_url":"https://rest.uniprot.org/uniprotkb/P10646.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10646/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10646"}},"corpus_meta":[{"pmid":"1832771","id":"PMC_1832771","title":"Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1832771","citation_count":459,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"355891","id":"PMC_355891","title":"Sequence of the lacI gene.","date":"1978","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/355891","citation_count":448,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3413731","id":"PMC_3413731","title":"Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).","date":"1988","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/3413731","citation_count":430,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7973627","id":"PMC_7973627","title":"Crystal structure of LacI member, PurR, bound to DNA: minor groove binding by alpha helices.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7973627","citation_count":343,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9271116","id":"PMC_9271116","title":"Null mutation of mCOUP-TFI results in defects in morphogenesis of the glossopharyngeal ganglion, axonal projection, and arborization.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9271116","citation_count":195,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19160499","id":"PMC_19160499","title":"Requirement for COUP-TFI and II in the temporal specification of neural stem cells in CNS development.","date":"2008","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19160499","citation_count":188,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17828260","id":"PMC_17828260","title":"COUP-TFI regulates the balance of cortical patterning between frontal/motor and sensory areas.","date":"2007","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17828260","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1660424","id":"PMC_1660424","title":"Spontaneous mutation in the Escherichia coli lacI gene.","date":"1991","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1660424","citation_count":186,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10624948","id":"PMC_10624948","title":"The nuclear orphan receptor COUP-TFI is required for differentiation of subplate neurons and guidance of thalamocortical axons.","date":"1999","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/10624948","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19269243","id":"PMC_19269243","title":"Allostery in the LacI/GalR family: variations on a theme.","date":"2009","source":"Current opinion in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19269243","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10899129","id":"PMC_10899129","title":"SsrA-mediated tagging and proteolysis of LacI and its role in the regulation of lac operon.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10899129","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26638884","id":"PMC_26638884","title":"Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies.","date":"2016","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/26638884","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11027229","id":"PMC_11027229","title":"Differential expression of COUP-TFI, CHL1, and two novel genes in developing neocortex identified by differential display PCR.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11027229","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20133588","id":"PMC_20133588","title":"Area-specific temporal control of corticospinal motor neuron differentiation by COUP-TFI.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20133588","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12871499","id":"PMC_12871499","title":"Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates.","date":"2003","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/12871499","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31218726","id":"PMC_31218726","title":"Epigenetic polypharmacology: A new frontier for epi-drug discovery.","date":"2019","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/31218726","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8979119","id":"PMC_8979119","title":"Tissue factor pathway inhibitor (TFPI)--an update.","date":"1996","source":"Haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/8979119","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33938389","id":"PMC_33938389","title":"Completion of the gut microbial epi-bile acid pathway.","date":"2021","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/33938389","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25035932","id":"PMC_25035932","title":"Modular, multi-input transcriptional logic gating with orthogonal LacI/GalR family chimeras.","date":"2014","source":"ACS synthetic biology","url":"https://pubmed.ncbi.nlm.nih.gov/25035932","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24966856","id":"PMC_24966856","title":"Comparative genomics and evolution of regulons of the LacI-family transcription factors.","date":"2014","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/24966856","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20002538","id":"PMC_20002538","title":"Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma.","date":"2009","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/20002538","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16056260","id":"PMC_16056260","title":"Tissue, cell and stage specificity of (epi)mutations in cancers.","date":"2005","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16056260","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35303428","id":"PMC_35303428","title":"TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficile.","date":"2022","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/35303428","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30878492","id":"PMC_30878492","title":"Primers on nutrigenetics and nutri(epi)genomics: Origins and development of precision nutrition.","date":"2019","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/30878492","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19630792","id":"PMC_19630792","title":"Regulation of TFPI function by protein S.","date":"2009","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/19630792","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1346095","id":"PMC_1346095","title":"Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.","date":"1992","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1346095","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21965613","id":"PMC_21965613","title":"COUP-TFI promotes radial migration and proper morphology of callosal projection neurons by repressing Rnd2 expression.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21965613","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14738874","id":"PMC_14738874","title":"The nuclear orphan receptor COUP-TFI is important for differentiation of oligodendrocytes.","date":"2004","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/14738874","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30920120","id":"PMC_30920120","title":"Chemoenzymatic Total Synthesis of Deoxy-, epi-, and Podophyllotoxin and a Biocatalytic Kinetic Resolution of Dibenzylbutyrolactones.","date":"2019","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/30920120","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36979957","id":"PMC_36979957","title":"Endometriosis: Update of Pathophysiology, (Epi) Genetic and Environmental Involvement.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36979957","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29709504","id":"PMC_29709504","title":"The pleiotropic transcriptional regulator COUP-TFI plays multiple roles in neural development and disease.","date":"2018","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/29709504","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19661488","id":"PMC_19661488","title":"Protein S as cofactor for TFPI.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19661488","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29996095","id":"PMC_29996095","title":"Neuron-Astroglia Cell Fate Decision in the Adult Mouse Hippocampal Neurogenic Niche Is Cell-Intrinsically Controlled by COUP-TFI In Vivo.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29996095","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30302740","id":"PMC_30302740","title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.","date":"2018","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/30302740","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19210754","id":"PMC_19210754","title":"Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis.","date":"2008","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19210754","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19212621","id":"PMC_19212621","title":"EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression.","date":"2009","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19212621","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21062455","id":"PMC_21062455","title":"TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21062455","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20553382","id":"PMC_20553382","title":"Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells.","date":"2010","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/20553382","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29845491","id":"PMC_29845491","title":"Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.","date":"2018","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/29845491","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22449186","id":"PMC_22449186","title":"Methylation of TFPI-2 is an early event of esophageal carcinogenesis.","date":"2012","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/22449186","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12093745","id":"PMC_12093745","title":"Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 through Ser118 phosphorylation by MAPK.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12093745","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20111703","id":"PMC_20111703","title":"Genome-wide analysis of binding sites and direct target genes of the orphan nuclear receptor NR2F1/COUP-TFI.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20111703","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31252410","id":"PMC_31252410","title":"The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.","date":"2019","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31252410","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19805348","id":"PMC_19805348","title":"Tetramer opening in LacI-mediated DNA looping.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19805348","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30170355","id":"PMC_30170355","title":"Epigenetics and Epi-miRNAs: Potential markers/therapeutics in leukemia.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30170355","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31395862","id":"PMC_31395862","title":"Sensory cortex wiring requires preselection of short- and long-range projection neurons through an Egr-Foxg1-COUP-TFI network.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31395862","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26813976","id":"PMC_26813976","title":"Gradient COUP-TFI Expression Is Required for Functional Organization of the Hippocampal Septo-Temporal Longitudinal Axis.","date":"2017","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/26813976","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26607136","id":"PMC_26607136","title":"Role of exosite binding modulators in the inhibition of Fxa by TFPI.","date":"2015","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/26607136","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35642676","id":"PMC_35642676","title":"Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.","date":"2022","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35642676","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25359215","id":"PMC_25359215","title":"TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25359215","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21530612","id":"PMC_21530612","title":"Knockdown of TFPI-2 promotes migration and invasion of glioma cells.","date":"2011","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/21530612","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22197177","id":"PMC_22197177","title":"Tissue factor/TFPI and blood cells.","date":"2011","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/22197177","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35911511","id":"PMC_35911511","title":"Epi-Drugs in Heart Failure.","date":"2022","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35911511","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9065996","id":"PMC_9065996","title":"Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus.","date":"1997","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/9065996","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27207418","id":"PMC_27207418","title":"Targeting TFPI for hemophilia treatment.","date":"2016","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/27207418","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17117414","id":"PMC_17117414","title":"The (epi)genetics of human synovial sarcoma.","date":"2007","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17117414","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26574286","id":"PMC_26574286","title":"Exploring LacI-DNA dynamics by multiscale simulations using the SIRAH force field.","date":"2015","source":"Journal of chemical theory and computation","url":"https://pubmed.ncbi.nlm.nih.gov/26574286","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17674191","id":"PMC_17674191","title":"COUP-TFI modulates estrogen signaling and influences proliferation, survival and migration of breast cancer cells.","date":"2007","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/17674191","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26501324","id":"PMC_26501324","title":"Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1.","date":"2015","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/26501324","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12956419","id":"PMC_12956419","title":"Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells.","date":"2003","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12956419","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11682620","id":"PMC_11682620","title":"EAR2 and EAR3/COUP-TFI regulate transcription of the rat LH receptor.","date":"2001","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11682620","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24227652","id":"PMC_24227652","title":"COUP-TFI controls activity-dependent tyrosine hydroxylase expression in adult dopaminergic olfactory bulb interneurons.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24227652","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11168401","id":"PMC_11168401","title":"COUP-TFI and COUP-TFII regulate expression of the NHE through a nuclear hormone responsive element with enhancer activity.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11168401","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26205296","id":"PMC_26205296","title":"RNA (Epi)genetics in cardiovascular diseases.","date":"2015","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26205296","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2300081","id":"PMC_2300081","title":"Specificity of spontaneous mutation in the lacI gene cloned into bacteriophage M13.","date":"1990","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/2300081","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27840169","id":"PMC_27840169","title":"A TFPI-1 peptide that induces degradation of bacterial nucleic acids, and inhibits bacterial and viral infection in half-smooth tongue sole, Cynoglossus semilaevis.","date":"2016","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27840169","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32620673","id":"PMC_32620673","title":"Remodeling the epigenome and (epi)cytoskeleton: a new paradigm for co-regulation by methylation.","date":"2020","source":"The Journal of experimental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32620673","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33570646","id":"PMC_33570646","title":"Concizumab: a novel anti-TFPI therapeutic for hemophilia.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/33570646","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11376693","id":"PMC_11376693","title":"LacI transgenic animal study: relationships among DNA-adduct levels, mutant frequencies and cancer incidences.","date":"2001","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/11376693","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25922524","id":"PMC_25922524","title":"Transcription factors COUP-TFI and COUP-TFII are required for the production of granule cells in the mouse olfactory bulb.","date":"2015","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25922524","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22425215","id":"PMC_22425215","title":"TFPI-dependent activities of protein S.","date":"2012","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/22425215","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9851803","id":"PMC_9851803","title":"COUP-TFI expression in human adrenocortical adenomas: possible role in steroidogenesis.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9851803","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9862192","id":"PMC_9862192","title":"Mutation studies in lacI transgenic mice after exposure to radiation or cyclophosphamide.","date":"1998","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/9862192","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27875740","id":"PMC_27875740","title":"Conditional knockout of TFPI-1 in VSMCs of mice accelerates atherosclerosis by enhancing AMOT/YAP pathway.","date":"2016","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27875740","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28916229","id":"PMC_28916229","title":"Japanese Leigh syndrome case treated with EPI-743.","date":"2017","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/28916229","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36351897","id":"PMC_36351897","title":"Identification of TFPI as a receptor reveals recombination-driven receptor switching in Clostridioides difficile toxin B variants.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36351897","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22405586","id":"PMC_22405586","title":"Hemostatic properties of a TFPI antibody.","date":"2012","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/22405586","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23347185","id":"PMC_23347185","title":"Direct inhibition of factor VIIa by TFPI and TFPI constructs.","date":"2013","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/23347185","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25120267","id":"PMC_25120267","title":"Multiple LacI-mediated loops revealed by Bayesian statistics and tethered particle motion.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25120267","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20723970","id":"PMC_20723970","title":"The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes.","date":"2010","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/20723970","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30601657","id":"PMC_30601657","title":"Engineering a New Class of Anti-LacI Transcription Factors with Alternate DNA Recognition.","date":"2019","source":"ACS synthetic biology","url":"https://pubmed.ncbi.nlm.nih.gov/30601657","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15760969","id":"PMC_15760969","title":"LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications.","date":"2005","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15760969","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17352822","id":"PMC_17352822","title":"Identification of a human TFPI-2 splice variant that is upregulated in human tumor tissues.","date":"2007","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17352822","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28039717","id":"PMC_28039717","title":"TFPI-2 expression is decreased in bladder cancer and is related to apoptosis.","date":"2016","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28039717","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8671718","id":"PMC_8671718","title":"Aflatoxin B1 induced lacI mutation in liver and kidney of transgenic mice C57BL/6N: effect of phorone.","date":"1996","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8671718","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17543441","id":"PMC_17543441","title":"Integration host factor alters LacI-induced DNA looping.","date":"2007","source":"Biophysical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17543441","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32903053","id":"PMC_32903053","title":"Diffusion-Weighted MRI to Assess Sacroiliitis: Improved Image Quality and Diagnostic Performance of Readout-Segmented Echo-Planar Imaging (EPI) Over Conventional Single-Shot EPI.","date":"2021","source":"AJR. American journal of roentgenology","url":"https://pubmed.ncbi.nlm.nih.gov/32903053","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25954015","id":"PMC_25954015","title":"A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25954015","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7686256","id":"PMC_7686256","title":"Large-scale mutational analysis of EMS-induced mutation in the lacI gene of Escherichia coli.","date":"1993","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/7686256","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7477049","id":"PMC_7477049","title":"Comparison of lacI and lacZ transgenic mouse mutation assays: an EU-sponsored interlaboratory study.","date":"1995","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/7477049","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2274917","id":"PMC_2274917","title":"Physical exercise enhances plasma levels of extrinsic pathway inhibitor (EPI).","date":"1990","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/2274917","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11209985","id":"PMC_11209985","title":"Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.","date":"2000","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11209985","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16646090","id":"PMC_16646090","title":"LacO-LacI interaction in affinity adsorption of plasmid DNA.","date":"2006","source":"Biotechnology and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/16646090","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7934956","id":"PMC_7934956","title":"Use of transgenic mouse lacI/Z mutation assays in genetic toxicology.","date":"1994","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/7934956","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8259547","id":"PMC_8259547","title":"The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.","date":"1993","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/8259547","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26342073","id":"PMC_26342073","title":"Flexibility and Disorder in Gene Regulation: LacI/GalR and Hox Proteins.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26342073","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19766631","id":"PMC_19766631","title":"COUP-TFI and -TFII nuclear receptors are expressed in amacrine cells and play roles in regulating the differentiation of retinal progenitor cells.","date":"2009","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/19766631","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26838850","id":"PMC_26838850","title":"F-127-PEI co-delivering docetaxel and TFPI-2 plasmid for nasopharyngeal cancer therapy.","date":"2015","source":"Materials science & engineering. C, Materials for biological applications","url":"https://pubmed.ncbi.nlm.nih.gov/26838850","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1658969","id":"PMC_1658969","title":"Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation.","date":"1991","source":"Thrombosis research. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/1658969","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11246540","id":"PMC_11246540","title":"Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.","date":"2001","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11246540","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391209","id":"PMC_10391209","title":"Characterization of single-nucleotide polymorphisms in coding regions of human genes.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391209","citation_count":1381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21378988","id":"PMC_21378988","title":"A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21378988","citation_count":561,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3422166","id":"PMC_3422166","title":"The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.","date":"1988","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3422166","citation_count":481,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2927510","id":"PMC_2927510","title":"Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor.","date":"1989","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2927510","citation_count":478,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2271516","id":"PMC_2271516","title":"Regulation of coagulation by a multivalent Kunitz-type inhibitor.","date":"1990","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2271516","citation_count":381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2452157","id":"PMC_2452157","title":"Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2452157","citation_count":334,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16488980","id":"PMC_16488980","title":"Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16488980","citation_count":261,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23583979","id":"PMC_23583979","title":"Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23583979","citation_count":250,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7598447","id":"PMC_7598447","title":"Tissue factor pathway inhibitor and the revised theory of coagulation.","date":"1995","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7598447","citation_count":233,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24620349","id":"PMC_24620349","title":"Biology of tissue factor pathway inhibitor.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24620349","citation_count":227,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3492226","id":"PMC_3492226","title":"Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.","date":"1987","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3492226","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17207965","id":"PMC_17207965","title":"hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes.","date":"2007","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17207965","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2553722","id":"PMC_2553722","title":"Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2553722","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11686353","id":"PMC_11686353","title":"Structure and biology of tissue factor pathway inhibitor.","date":"2001","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11686353","citation_count":200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26603155","id":"PMC_26603155","title":"Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.","date":"2015","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26603155","citation_count":157,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16261634","id":"PMC_16261634","title":"Tissue factor pathway inhibitor: structure, biology and involvement in disease.","date":"2006","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16261634","citation_count":154,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3024756","id":"PMC_3024756","title":"Characterization of the inhibition of tissue factor in serum.","date":"1987","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/3024756","citation_count":150,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26439863","id":"PMC_26439863","title":"Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef.","date":"2015","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/26439863","citation_count":146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16380494","id":"PMC_16380494","title":"Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/16380494","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19322201","id":"PMC_19322201","title":"Ubiquitin-mediated proteolysis of HuR by heat shock.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19322201","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24127605","id":"PMC_24127605","title":"Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24127605","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45656,"output_tokens":5681,"usd":0.111091},"stage2":{"model":"claude-opus-4-6","input_tokens":9222,"output_tokens":2768,"usd":0.172965},"total_usd":0.668082,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59312,"output_tokens":8440,"usd":0.152268},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11836,"output_tokens":3813,"usd":0.231758}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"TFPI (then called EPI, Extrinsic Pathway Inhibitor) is produced in endothelial cells and is released into the circulation by heparin, with heparin inducing a dose-dependent increase in TFPI activity in vivo.\",\n      \"method\": \"In vitro heparin addition to plasma/blood, in vivo heparin injection studies, gel filtration of endothelial cell culture supernatant\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro and in vivo methods in a single lab; endothelial cell origin supported by gel filtration\",\n      \"pmids\": [\"3413731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Physical exercise causes significant release of TFPI (EPI) from the endothelium into plasma, with levels peaking ~2 hours after prolonged strenuous exercise, suggesting TFPI can be mobilized from endothelial stores in vivo.\",\n      \"method\": \"Measurement of plasma EPI levels before, during, and after exercise of varying durations in healthy subjects\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — observational in vivo study, single cohort, no direct mechanistic dissection\",\n      \"pmids\": [\"2274917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"TFPI (EPI) released after in vivo heparin administration is a major contributor to the post-heparin anticoagulant effect in tissue thromboplastin-induced coagulation, as demonstrated by blocking TFPI with polyclonal antibodies.\",\n      \"method\": \"In vivo heparin administration, neutralization with polybrene, blocking TFPI with polyclonal antibodies, clotting time and fibrinopeptide A release assays\",\n      \"journal\": \"Thrombosis research. Supplement\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional blocking antibody experiments combined with in vivo/ex vivo coagulation assays\",\n      \"pmids\": [\"1658969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"TFPI (LACI) acts as a cofactor for heparin in inhibiting tissue factor-induced coagulation; TFPI and heparin act synergistically, and TFPI-depleted plasma shows only linear prolongation of PT in response to heparin, while normal plasma shows threshold-dependent full anticoagulation. Sulfated polysaccharides including LMWH, dermatan sulfate, and heparan sulfate all cooperate with LACI in this manner.\",\n      \"method\": \"PT and APTT assays in TFPI-depleted and normal plasma, supplementation with purified recombinant LACI and various sulfated polysaccharides\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution experiments with depleted plasma and purified recombinant TFPI, multiple polysaccharide conditions tested\",\n      \"pmids\": [\"1346095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"TFPI is most potent in the extrinsic (PT) coagulation assay compared to APTT; the anticoagulant effect of TFPI in normal plasma is pronounced especially at prolonged clotting times and in combination with antithrombin/heparin; ATIII/heparin complex is required for heparin to augment TFPI's effect.\",\n      \"method\": \"Comparison of TFPI, heparin, hirudin in APTT and PT assays; TFPI blocking in warfarin-treated patient plasma; ATIII-deficient plasma experiments\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple assay conditions, ATIII-deficient plasma, antibody blocking in patient plasma\",\n      \"pmids\": [\"8259547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TFPI is constitutively produced by endothelial cells, where it is largely bound to the endothelial cell surface; it is rapidly released by heparin and other negatively charged ions; in other cell lines, TFPI degradation is mediated by the LDL receptor-related protein (LRP), which may be important for its clearance.\",\n      \"method\": \"Review summarizing cell biology, immunodepletion, infusion and binding studies\",\n      \"journal\": \"Haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesizing experimental findings from multiple studies; LRP involvement supported by prior experimental work cited\",\n      \"pmids\": [\"8979119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In neonates, concomitantly low levels of TFPI (~50% of adult values) and antithrombin together allow sufficient thrombin generation in response to low tissue factor concentrations, explaining adequate hemostasis in neonates despite low procoagulant factor levels.\",\n      \"method\": \"In vitro coagulation assays with cord plasma vs. adult plasma using lipidated tissue factor at varying concentrations; measurement of FXa generation, thrombin generation, and clotting times\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in vitro functional comparison in plasma with defined TF concentrations\",\n      \"pmids\": [\"12871499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Protein S acts as a cofactor for full-length TFPI, stimulating inhibition of factor Xa by TFPI approximately 10-fold; protein S and TFPI form a complex in plasma (confirmed by surface plasmon resonance), and full-length TFPI levels are reduced in protein S-deficient states, contributing to hypercoagulability.\",\n      \"method\": \"Thrombin generation assay (calibrated automated thrombography), protein S immunodepletion, surface plasmon resonance, plasma antigen measurements in protein S-deficient patients\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — SPR for direct binding, functional thrombin generation assays, immunodepletion, replicated by independent measurements in patient cohorts\",\n      \"pmids\": [\"20002538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Protein S acts as a cofactor of TFPI by stimulating inhibition of factor Xa by TFPI; the TFPI/protein S system particularly inhibits the TF pathway at low procoagulant stimuli; at high TF concentrations the system fails to regulate FXa generation, but regains activity in the presence of APC.\",\n      \"method\": \"Biochemical assays with purified proteins and plasma; thrombin generation measurements; mechanistic review integrating cofactor assay data\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical assays, replicated across labs\",\n      \"pmids\": [\"19661488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TFPI transgenic expression on porcine aortic endothelial cells inhibits tissue factor activity induced by anti-nonGal IgG antibodies, demonstrating that cell-surface TFPI can suppress complement-independent TF-mediated coagulation triggered by xenoreactive antibodies.\",\n      \"method\": \"TF activity assay on PAECs from TFPI-transgenic pigs, wild-type, and CD46-transgenic pigs incubated with baboon serum; comparison with atorvastatin treatment and anti-IgG Fab antibody pretreatment\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic animal model with functional TF activity assays and multiple control conditions\",\n      \"pmids\": [\"20553382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TFPI is co-expressed with tissue factor on human monocyte surfaces after LPS stimulation; surface TFPI (both TFPIα and TFPIβ isoforms) regulates monocyte TF procoagulant activity as demonstrated by blocking with anti-TFPI IgG, which significantly enhanced TF activity and thrombin generation.\",\n      \"method\": \"RT-qPCR for TFPI/TF mRNA isoforms, flow cytometry, confocal microscopy, TF activity assay, Calibrated Automated Thrombogram on PBMCs with anti-TFPI IgG blocking\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (mRNA, surface antigen, functional assay, antibody blocking) in single lab\",\n      \"pmids\": [\"20723970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TFPI regulates tissue factor/FVIIa activity by binding and inhibiting FXa, subsequently forming an inactive quaternary complex with TF-FVIIa-FXa; TF is expressed exclusively in monocytes in healthy individuals' blood.\",\n      \"method\": \"Review of experimental literature on TF/TFPI distribution in blood cells; mechanistic description supported by referenced in vitro activity studies\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesizing mechanistic data; quaternary complex mechanism supported by prior experimental literature\",\n      \"pmids\": [\"22197177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TFPI-mediated inhibition of FXa is potentiated by protein S; protein S stimulates the TFPI/protein S system in both the presence and absence of APC; the TFPI/protein S anticoagulant system is intertwined with APC anticoagulant activity in plasma, making TFPI a major determinant of APC anticoagulant activity.\",\n      \"method\": \"Biochemical assays with purified components, plasma thrombin generation assays\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical assays with purified proteins and plasma, mechanistic integration from multiple studies\",\n      \"pmids\": [\"22425215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TFPI inhibits FVIIa directly; the Kunitz-2 (KD2) domain contributes to FVIIa inhibition; the KD3-C-terminus significantly enhances direct FVIIa inhibition by full-length TFPI and is required for optimal TF-FVIIa inhibition; a tight quaternary TF-FVIIa-TFPI-FXa complex forms with Ki <0.15 nM for full-length TFPI; phospholipids and the Gla-domain of FXa are required for quaternary complex formation; protein S stimulates TF-FVIIa inhibition by TFPI.\",\n      \"method\": \"Chromogenic substrate assays with full-length TFPI and truncated TFPI constructs (TFPI1-150, KD1-KD2, KD1); comparison with/without TF, phospholipids, protein S, FXa\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with multiple truncated constructs and domain deletions, quantitative Ki measurements across multiple conditions\",\n      \"pmids\": [\"23347185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TFPI inhibits the lectin pathway of complement activation by directly interacting with and inhibiting MASP-2, without affecting MASP-1 or classical pathway proteases C1s/C1r; this inhibition requires the Kunitz-2 domain of TFPI.\",\n      \"method\": \"Ex vivo LP complement assay (C4 deposition on mannan-coated plates), fluid-phase chromogenic MASP-2 activity assay, domain mapping with monoclonal antibodies against TFPI domains\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct functional inhibition assay, domain-specific antibody mapping, multiple complement pathways tested as controls\",\n      \"pmids\": [\"25359215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Full-length TFPI inhibits FXa with t½ of 3–15 minutes at physiological concentrations; phospholipids (~10 µM) stimulate FXa inhibition by TFPI up to 5-6-fold; unfractionated heparin enhances FXa inhibition ~8-fold at optimal concentrations; physiological protein S and FV both enhance FXa inhibition 2-3-fold; thrombin-activated FVa impairs TFPI inhibition of FXa; TFPI cannot effectively inhibit FXa-catalysed prothrombin activation in the FVa-assembled prothrombinase complex; modulating effects of phospholipids, heparin, protein S, FV/FVa require the KD3-C-terminus of TFPI.\",\n      \"method\": \"Progress curve analysis with chromogenic substrate CS11-65 for FXa; full-length TFPI vs. TFPI1-150; multiple physiological modulators tested at physiological concentrations\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative in vitro reconstitution with purified components, multiple modulators, domain-truncated constructs, comprehensive mechanistic mapping\",\n      \"pmids\": [\"26607136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TFPI-1 interacts with angiomotin (AMOT) in human vascular smooth muscle cells; TFPI-1 deficiency reduces phosphorylation of AMOT and YAP (Yes-associated protein 1), leading to increased SLUG and CTGF expression via the Hippo signaling pathway, promoting VSMC proliferation and migration and accelerating atherosclerosis.\",\n      \"method\": \"Conditional TFPI-1 knockout in VSMCs on ApoE-/- background; mass spectrometry, immunoprecipitation, co-localization analyses to identify AMOT interaction; Western blot for AMOT/YAP phosphorylation; real-time PCR for target genes\",\n      \"journal\": \"International journal of cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout mouse model, MS-identified novel interaction confirmed by Co-IP, downstream signaling pathway validated by Western blot\",\n      \"pmids\": [\"27875740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A balance between TFPI activity and thrombin-mediated platelet activation (via PAR4) is required for murine embryonic development; Tfpi-/- embryonic lethality from DIC is rescued by concomitant PAR4 deficiency, demonstrating that TFPI physiologically modulates thrombin-dependent platelet activation in vivo.\",\n      \"method\": \"Genetic epistasis: Tfpi+/- x Par4-/- crosses, survival analysis, histology (fibrin deposition, inflammation), thrombin-antithrombin complex measurement, venous electrolytic injury model, TF-induced pulmonary embolism model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rigorous genetic epistasis in mice with multiple mechanistic readouts (embryonic rescue, coagulation markers, injury models)\",\n      \"pmids\": [\"25954015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TFPI is a multivalent Kunitz-type serine protease inhibitor that regulates tissue factor-induced coagulation through FXa-dependent feedback inhibition of the TF-FVIIa complex; the second Kunitz domain (KD2) mediates binding to and inhibition of FXa; monoclonal antibody concizumab targeting KD2 restores thrombin generation in FVIII/FIX-deficient plasma.\",\n      \"method\": \"Antibody binding domain mapping (KD2), thrombin generation assays in hemophilia A/B plasma, rabbit hemophilia model, phase 1 clinical pharmacodynamics\",\n      \"journal\": \"Drugs\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain-specific antibody mechanistic studies, functional thrombin generation assays, in vivo hemophilia model\",\n      \"pmids\": [\"29845491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Concizumab binds to the Kunitz-2 domain of TFPI and prevents TFPI from binding to and blocking the FXa active site, thereby increasing FXa and thrombin generation; this mechanism is effective regardless of FVIII or FIX status and does not interfere with coagulation regulation downstream of TFPI.\",\n      \"method\": \"Phase 2 clinical trials with pharmacodynamic measurements (TFPI levels, thrombin generation peak/ETP, D-dimer, prothrombin F1+2, annualized bleeding rates)\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clinical pharmacodynamics with mechanistic readouts confirm KD2-mediated FXa inhibition as TFPI's key anticoagulant mechanism\",\n      \"pmids\": [\"33570646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TFPI is a cell-surface receptor for TcdB variants (TcdB2 and TcdB4) from hypervirulent clade 2 Clostridioides difficile; TFPI is recognized by a region in TcdB4 homologous to the FZD-binding site in TcdB1; cryo-EM structure of full-length TcdB4 bound to TFPI defines the receptor-binding region; TFPI is highly expressed in intestinal glands/colonic crypts; recombinant TFPI protects colonic epithelium from TcdB2/4.\",\n      \"method\": \"CRISPR/Cas9 genome-wide screens, cryo-EM structure determination of TcdB4-TFPI complex, cell-based toxin protection assays with recombinant TFPI, mutagenesis of receptor-binding residues\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — CRISPR screen for receptor identification, cryo-EM structure, mutagenesis, functional protection assays — multiple orthogonal methods\",\n      \"pmids\": [\"35303428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TFPI acts as a host receptor for multiple TcdB subtypes (TcdB4, TcdB7-subset, TcdB10); TFPI recognition by TcdB is defined by a 6-residue haplotype (B4/B7) in the receptor-binding region; intragenic micro-recombination events in the TcdB receptor-binding region drive switching between TFPI- and FZD-binding capabilities; introduction of B4/B7-haplotype residues into TcdB1 enables dual recognition of TFPI and FZDs; TcdB10 binds TFPI in a species-selective manner.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 screens, sequence analysis of 206 TcdB variants, site-directed mutagenesis of receptor-binding residues, cell-based toxin binding and cytotoxicity assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — CRISPR screens, comprehensive mutagenesis, functional assays across multiple TcdB variants and species\",\n      \"pmids\": [\"36351897\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TFPI is a multivalent Kunitz-type serine protease inhibitor constitutively produced and surface-anchored on endothelial cells and monocytes, which inhibits the extrinsic coagulation pathway through a sequential mechanism: Kunitz-2 (KD2) binds and inhibits FXa, and the resulting TFPI-FXa complex then inhibits TF-FVIIa to form a tight quaternary TF-FVIIa-FXa-TFPI complex (requiring phospholipids and the FXa Gla-domain); protein S acts as a cofactor ~10-fold stimulating FXa inhibition by full-length TFPI; heparin releases TFPI from endothelial surfaces and synergizes with TFPI and antithrombin to suppress TF-driven coagulation; TFPI also inhibits MASP-2 of the lectin complement pathway via KD2; in vascular smooth muscle cells TFPI interacts with AMOT to modulate Hippo/YAP signaling and suppress proliferation/migration; and TFPI serves as a cell-surface receptor exploited by hypervirulent C. difficile TcdB variants for colonic epithelial entry.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification:**\n\nFrom the main corpus (100 papers):\n- Papers 1, 2, 8, 65, 89: lacI (bacterial lac repressor) — EXCLUDE (symbol collision)\n- Papers 4, 10, 19, 20, 44, 57, 79, 81, 82, 86, 93, 96: LacI/GalR family — EXCLUDE\n- Papers 5, 6, 7, 9, 13, 14, 27, 28, 31, 33, 41, 42, 46, 47, 58, 62, 63, 70, 72, 97: COUP-TFI (NR2F1) — EXCLUDE (alias collision)\n- Papers 12, 16, 18, 22, 24, 29, 30, 35, 43, 45, 49, 53, 56, 64, 67, 87: epigenetics/other — EXCLUDE\n- Papers 36, 37, 38 (partial), 40, 51, 59, 60, 83, 84, 98: TFPI-2 (different gene, TFPI2) — EXCLUDE\n- Papers 69, 73, 85, 90, 94: lacI transgenic mouse — EXCLUDE\n- Papers 11, 61: other genes — EXCLUDE\n- Papers 23, 76: TFPI as C. difficile receptor — KEEP\n- Papers 3, 15 (EPI/TFPI release by heparin), 17, 21, 25, 26, 32, 34, 38 (TFPI transgenic), 39, 48, 50, 52, 54, 55, 66, 68, 71, 74, 77, 78, 80, 88, 91, 92, 95, 99, 100: KEEP (canonical TFPI)\n\nFrom gene2pubmed papers:\n- Papers 1,2,3,4,5,6,7,10,11,16,20,23,27,28,29: not TFPI-specific — EXCLUDE\n- Papers 8, 9, 12, 14, 15, 17, 18, 19, 21, 22, 24, 25, 26, 30: canonical TFPI — KEEP\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"LACI (later renamed TFPI) directly inhibits factor Xa at or near its active site, and in a factor Xa-dependent manner inhibits the factor VIIa/tissue factor (TF) complex, consistent with formation of a quaternary VIIa-TF-Xa-LACI complex. The gamma-carboxyglutamic acid (Gla) domain of factor Xa is required for this quaternary complex formation and for efficient TF/VIIa inhibition.\",\n      \"method\": \"In vitro chromogenic substrate assay, nondenaturing PAGE complex detection, Gla-domain-deleted factor Xa competition experiments, antibody inhibition studies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with multiple orthogonal methods; foundational mechanistic study replicated across labs\",\n      \"pmids\": [\"3422166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"LACI/TFPI is encoded by a cDNA predicting a 276-residue mature protein with three tandem Kunitz-type serine protease inhibitory domains, a negatively charged N-terminus, and a positively charged C-terminus, with multiple molecular weight forms in plasma associated with apolipoprotein A-II via mixed disulfide bonds.\",\n      \"method\": \"cDNA cloning, nucleotide sequencing, Northern blot, 125I-factor Xa binding assay, lambda gt11 library screening with polyclonal antiserum\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cDNA sequence with direct protein validation and functional binding assay; foundational structural discovery\",\n      \"pmids\": [\"2452157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Inhibition of TF activity by the extrinsic pathway inhibitor (EPI/TFPI) requires the simultaneous presence of factor VIIa/TF, factor Xa (with active site intact), calcium, and EPI; the inhibition is reversible and factor VIIa/TF activity can be recovered from a dissociated inhibited complex. Preliminary incubation of EPI with factor Xa alone or factor VIIa/TF alone does not substitute for simultaneous presence of all components.\",\n      \"method\": \"Activated peptide release assay using 3H-factor IX substrate, plasma reconstitution experiments with purified/depleted components, EPI supplementation and antibody blocking\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple reconstitution experiments with defined components; replicated in subsequent studies\",\n      \"pmids\": [\"3492226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The TF inhibitory activity present in serum (later identified as TFPI) requires factor VII(a), catalytically active factor Xa, and an additional plasma component present in BaSO4-absorbed serum. HepG2 hepatoma cells secrete this inhibitory activity in vitro, identifying endothelium/liver as a source of TFPI.\",\n      \"method\": \"Clotting assay using crude TF with immunodepleted and BaSO4-absorbed plasma fractions; HepG2 conditioned media assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple plasma-fractionation approaches, cell culture validation; foundational identification of TFPI activity\",\n      \"pmids\": [\"3024756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Site-directed mutagenesis of each of the three Kunitz domains of LACI/TFPI revealed that Kunitz domain 2 (K2) is required for efficient binding and inhibition of factor Xa, and that both K1 and K2 are required for inhibition of VIIa/TF; K3 active-site mutation has no significant effect on either function. This established the domain-function map: K1 binds VIIa/TF active site, K2 binds Xa active site.\",\n      \"method\": \"Site-directed mutagenesis of active-site residues in each Kunitz domain, followed by functional assays for Xa inhibition and VIIa/TF inhibition in vitro\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct active-site mutagenesis with quantitative functional readout; foundational domain mapping study\",\n      \"pmids\": [\"2927510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Plasma LACI/TFPI was purified and shown to exist in multiple molecular weight forms (40–130 kDa); the 46-kDa and larger forms are associated with apolipoprotein A-II via mixed disulfide linkages. LDL contains primarily the 40-kDa form while HDL contains primarily the LACI/apoA-II complex form, with ~50% of plasma TFPI associated with LDL/VLDL.\",\n      \"method\": \"Sequential hydrophobic, ion-exchange, and affinity chromatography purification; SDS-PAGE; N-terminal sequencing; lipoprotein fractionation; gel filtration\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — protein purification with biochemical characterization; lipoprotein association directly demonstrated\",\n      \"pmids\": [\"2553722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Heparin induces release of EPI (TFPI) from endothelial cells into the circulation in a dose-dependent manner following intravenous injection, an effect not abolished by polybrene or anti-antithrombin antibodies, suggesting active secretion from endothelial stores rather than antithrombin displacement. Gel filtration of endothelial cell culture supernatant reveals a single inhibitory fraction at ~43 kDa.\",\n      \"method\": \"Chromogenic substrate assay for EPI activity in plasma; in vivo heparin injection in humans; gel filtration of endothelial cell conditioned medium; polybrene neutralization and antibody blocking controls\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (in vitro cell culture + in vivo human pharmacology + antibody controls); replicated in subsequent studies\",\n      \"pmids\": [\"3413731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"TFPI (LACI) acts as a cofactor for heparin in inhibiting tissue factor-induced coagulation: in LACI-depleted plasma, heparin causes only moderate linear prolongation of prothrombin time, while normal plasma shows greater and threshold-dependent anticoagulation at the same heparin concentrations, demonstrating synergistic anticoagulant action between LACI and sulfated polysaccharides.\",\n      \"method\": \"APTT and modified prothrombin time assays with LACI-depleted plasma reconstituted with purified recombinant LACI; titration with unfractionated heparin and various sulfated polysaccharides\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of depleted plasma with purified recombinant protein; dose-response characterization; replicated finding\",\n      \"pmids\": [\"1346095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"TFPI regulates tissue factor-induced coagulation as a multivalent Kunitz-type inhibitor, directly inhibiting activated factor X and producing feedback inhibition of the factor VIIa/tissue factor catalytic complex in a factor Xa-dependent manner.\",\n      \"method\": \"Biochemical reconstitution, enzyme kinetics, plasma coagulation assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic reconstitution study; foundational description of TFPI as a multivalent inhibitor\",\n      \"pmids\": [\"2271516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"EPI (TFPI) is released into blood during extensive physical exercise (30 km cross-country skiing or long-distance running), with peak plasma EPI levels reached 2 hours post-exercise, suggesting mobilization from endothelial stores and possibly from lipoprotein-associated pools due to exercise-induced lipoprotein lipase activity.\",\n      \"method\": \"EPI plasma activity assay in athletes before and after exercise of various durations; plasma volume-corrected measurements\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single in vivo observational study measuring TFPI release; no direct mechanistic dissection\",\n      \"pmids\": [\"2274917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"EPI (TFPI) released in vivo by heparin significantly contributes to the post-heparin anticoagulant effect (prolonged clotting time and retarded fibrinopeptide A release) as demonstrated by blocking with polyclonal anti-EPI antibodies in post-heparin plasma, including plasma from cancer patients.\",\n      \"method\": \"Polybrene neutralization of heparin followed by TTP/CaCl2-triggered coagulation; polyclonal blocking antibody addition; clotting time and fibrinopeptide A release assay\",\n      \"journal\": \"Thrombosis research supplement\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — blocking antibody approach demonstrates functional contribution of TFPI to post-heparin anticoagulation\",\n      \"pmids\": [\"1658969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"TFPI is a major anticoagulant in normal plasma specifically in the extrinsic (tissue factor) pathway, with its effect particularly pronounced at prolonged clotting times and enhanced by the simultaneous presence of other anticoagulants (heparin/antithrombin); blocking TFPI in warfarin-treated plasma significantly shortens clotting times. The TFPI/antithrombin cooperation is dependent on antithrombin anticoagulant activity.\",\n      \"method\": \"APTT and PT clotting assays with TFPI-depleted plasma, TFPI/heparin/hirudin combinations, ATIII-deficient plasma, warfarin-treated plasma; polyclonal antibody depletion\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic plasma depletion/reconstitution experiments defining TFPI's quantitative contribution to anticoagulation\",\n      \"pmids\": [\"8259547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TFPI structure comprises three Kunitz domains with defined functions: K1 inhibits factor VIIa complexed to tissue factor, K2 inhibits factor Xa, and K3 has no demonstrated direct protease-inhibiting function. The C-terminal basic region is required for rapid physiological inhibition of coagulation and for inhibition of smooth muscle cell proliferation, and plays an important role in cell surface binding.\",\n      \"method\": \"Structural analysis, domain-deletion studies, cell proliferation assays, binding studies reviewed from multiple primary sources\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — synthesis of mutagenesis, structural, and cell-based experiments from multiple independent studies\",\n      \"pmids\": [\"11686353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Protein S stimulates inhibition of factor Xa by full-length TFPI approximately 10-fold by reducing the Ki of the FXa/TFPI complex from 4.4 nM to 0.5 nM. This cofactor activity of protein S is specific to full-length TFPI (not truncated forms) and brings TFPI inhibitory concentration into the physiologically relevant plasma range, demonstrating that protein S and TFPI act together to inhibit TF activity.\",\n      \"method\": \"Purified protein reconstitution with chromogenic substrate assay for FXa inhibition; kinetic analysis (Ki determination); thrombin generation assays in plasma\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative kinetic reconstitution with purified proteins; Ki measured directly; supported by plasma thrombin generation assays\",\n      \"pmids\": [\"16488980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Full-length TFPI and protein S form a complex in plasma as demonstrated by protein S immunodepletion experiments and surface plasmon resonance, which reduces full-length TFPI levels in hereditary and acquired protein S deficiency. The co-deficiency of TFPI substantially contributes to the hypercoagulable state associated with protein S deficiency.\",\n      \"method\": \"Plasma immunodepletion of protein S, TFPI antigen measurement by ELISA, surface plasmon resonance binding analysis, thrombin generation by calibrated automated thrombography\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding confirmed by SPR; functional consequence shown by thrombin generation; protein S depletion/normalization experiments\",\n      \"pmids\": [\"20002538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Direct inhibition of TF-bound FVIIa by full-length TFPI requires contributions from multiple domains: K2 alone is a poor TF-FVIIa inhibitor (Ki=434 nM); K1-K2 improves this; the K3-C-terminus further enhances FVIIa inhibition (~7–10-fold) though is not essential for quaternary TF-FVIIa-TFPI-FXa complex formation. In the quaternary complex, Ki values drop to <0.15 nM for full-length TFPI. Phospholipids and the Gla-domain of FXa are required for quaternary complex formation. Protein S further stimulates TF-FVIIa inhibition by full-length TFPI.\",\n      \"method\": \"Chromogenic substrate assay for FVIIa activity; truncated TFPI constructs (KD1, KD1-KD2, TFPI1-150, full-length); relipidated and soluble TF; kinetic analysis; protein S and phospholipid titrations\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic domain-deletion analysis with quantitative kinetics; multiple orthogonal construct comparisons\",\n      \"pmids\": [\"23347185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TFPIα produces isoform-specific rapid inhibition of prothrombinase (FXa/FVa/phospholipid/Ca2+ complex) during coagulation initiation, mediated through a high-affinity exosite interaction between the basic C-terminus of TFPIα and an acidic region in the factor V/Va B domain retained in FXa-activated and platelet-derived FVa. This inhibitory activity is absent in TFPIβ and is lost after thrombin cleaves the acidic region from FVa.\",\n      \"method\": \"Purified prothrombinase reconstitution assays; TFPIα/TFPIβ isoform comparison; factor Va B-domain acidic region deletion mutants; platelet-derived FVa testing; thrombin cleavage experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution, mutagenesis, isoform comparison, and mechanistic dissection in a single study; novel anticoagulant function established\",\n      \"pmids\": [\"24127605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TFPIα and TFPIβ are alternatively spliced isoforms with distinct expression patterns and anticoagulant activities: TFPIα is the only isoform in platelets, while endothelial cells produce both isoforms (secreting TFPIα and expressing TFPIβ on the cell surface via GPI anchor). TFPIβ is a potent surface inhibitor of TF-FVIIa on endothelial cells; TFPIα contains a unique basic C-terminus that interacts with factor V B domain to inhibit prothrombinase during coagulation initiation.\",\n      \"method\": \"Isoform characterization via alternative splicing analysis; cell-type expression studies; GPI anchor validation; platelet vs. endothelial cell functional comparison; review of primary reconstitution data\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — synthesis of multiple primary mechanistic studies defining isoform-specific biochemistry and localization\",\n      \"pmids\": [\"24620349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Physiological concentrations of phospholipids (~10 µM negatively charged) enhance FXa inhibition by full-length TFPI 5–6-fold. Unfractionated heparin at 0.2–1 U/ml enhances FXa inhibition ~8-fold but impairs inhibition at >1 U/ml. Protein S and factor V (but not thrombin-activated FVa) each enhance FXa inhibition 2–3-fold, while FVa impairs TFPI-mediated FXa inhibition. TFPI fails to inhibit FXa-catalyzed prothrombin activation in the presence of FVa (prothrombinase). These modulatory effects are absent for truncated TFPI1-150, identifying the K3-C-terminus as essential for exosite-mediated regulation.\",\n      \"method\": \"Progress curve analysis with chromogenic substrate CS11-(65); systematic titration of phospholipids, heparin, prothrombin, FV, FVa, protein S; full-length vs. truncated TFPI comparison\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic quantitative kinetics with purified components; multiple modulators tested; structural domain attribution via truncation\",\n      \"pmids\": [\"26607136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TFPI selectively inhibits MASP-2 of the lectin pathway of complement without affecting MASP-1, C1s, or C1r, thus acting as an inhibitor of complement activation. The Kunitz-2 domain of TFPI is required for MASP-2 inhibition. This was demonstrated using rTFPI, MASP-2 chromogenic assay, C4-deposition assay, and domain-specific blocking monoclonal antibodies.\",\n      \"method\": \"Ex vivo lectin pathway activation on mannan-coated plates (C4 deposition assay); fluid-phase MASP-2 chromogenic assay; domain-specific anti-TFPI monoclonal antibodies to map K2 requirement\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with domain mapping via blocking antibodies; single lab but multiple complementary assays\",\n      \"pmids\": [\"25359215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Surface TFPI on human monocytes acts as an important regulator of monocyte procoagulant reactivity: pre-incubation of LPS-stimulated PBMCs with anti-TFPI IgG significantly enhanced TF activity, shortened lag-time, and increased thrombin generation. LPS stimulation causes parallel upregulation of both TFPIα and TFPIβ mRNA isoforms on monocyte surfaces, where TFPI co-localizes with TF.\",\n      \"method\": \"RT-qPCR for TFPI mRNA isoforms; flow cytometry and confocal microscopy for surface presentation; TF activity assay; calibrated automated thrombogram (CAT); anti-TFPI IgG blocking\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blocking with functional readout; co-localization; isoform quantification; single lab\",\n      \"pmids\": [\"20723970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A balance between TFPI anticoagulant activity and thrombin-mediated platelet activation via PAR4 is required for murine embryonic development. PAR4 deficiency (but not PAR3 deficiency) partially rescues >40% of Tfpi-null (Tfpi−/−) embryos from lethal disseminated intravascular coagulation, demonstrating that TFPI physiologically modulates thrombin-dependent platelet activation in vivo. Adult Tfpi−/−:Par4−/− mice show focal liver fibrin deposition and elevated thrombin-antithrombin complexes, indicating that TFPI dampens intravascular procoagulant stimuli even without thrombin-mediated platelet activation.\",\n      \"method\": \"Genetic epistasis (Tfpi+/−:Par4−/− crosses); survival analysis; immunohistochemistry for fibrin(ogen); plasma thrombin-antithrombin complex measurement; venous electrolytic injury model; TF-induced pulmonary embolism model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (double knockout rescue) with multiple in vivo phenotypic readouts; defines TFPI-PAR4 functional axis\",\n      \"pmids\": [\"25954015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Conditional knockout of TFPI-1 in vascular smooth muscle cells (VSMCs) of ApoE−/− mice accelerates atherosclerosis with increased VSMC proliferation and migration. By mass spectrometry, immunoprecipitation, and co-localization, TFPI-1 was found to interact with angiomotin (AMOT) in human VSMCs. TFPI-1 deficiency decreases AMOT and YAP phosphorylation, leading to increased expression of SLUG and CTGF (Hippo pathway targets linked to atherosclerosis).\",\n      \"method\": \"Conditional knockout mouse model (Tfpi1fl/fl/Sma-Cre+ApoE−/−); Sudan IV staining; immunohistochemistry; mass spectrometry identification of AMOT as binding partner; Co-IP and co-localization; Western blot for AMOT/YAP phosphorylation; qPCR for target genes\",\n      \"journal\": \"International journal of cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with in vivo phenotype + Co-IP/MS identification of AMOT interaction + signaling pathway changes; single lab\",\n      \"pmids\": [\"27875740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Low TFPI and low antithrombin levels in neonates (~50% of adult values) act synergistically to allow sufficient thrombin generation at low tissue factor concentrations, explaining the clinically excellent hemostasis of neonates despite reduced procoagulant factors. At <10 pmol/L lipidated TF, cord plasma clots faster and generates more free thrombin (~90% of adult value) than adult plasma due to combined low TFPI and antithrombin.\",\n      \"method\": \"In vitro clotting assay with lipidated TF titration; factor Xa generation and thrombin generation assays in neonatal cord plasma vs. adult plasma; TFPI and antithrombin concentration measurements\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional plasma reconstitution experiments demonstrating TFPI's quantitative contribution to neonatal hemostasis\",\n      \"pmids\": [\"12871499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Transgenic expression of TFPI on porcine aortic endothelial cells (PAECs) inhibits TF activity induced by anti-nonGal IgG binding via a complement-independent pathway, effectively preventing coagulation dysregulation in a xenotransplantation model. Atorvastatin or anti-IgG Fab antibody similarly inhibits TF expression.\",\n      \"method\": \"PAEC culture from wild-type, GT-KO, CD46-transgenic, and TFPI-transgenic pigs; TF activity assay; incubation with naive and sensitized baboon serum; heat inactivation and antibody blocking controls\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic cell expression with functional TF activity assay; defined mechanistic context\",\n      \"pmids\": [\"20553382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TFPI is identified as the colonic crypt receptor for TcdB variants (TcdB2 and TcdB4) from hypervirulent clade 2 Clostridioides difficile. CRISPR/Cas9 genome-wide screens identified TFPI as the receptor for TcdB4. Cryo-EM structure of full-length TcdB4 in complex with TFPI defined the receptor-binding region. TFPI is highly expressed in intestinal glands, and recombinant TFPI protects the colonic epithelium from TcdB2/4 toxin.\",\n      \"method\": \"CRISPR/Cas9 genome-wide loss-of-function screen; cryo-EM structure determination of TcdB4-TFPI complex; TFPI expression analysis in intestinal tissue; recombinant TFPI protection assay of colonic epithelium\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — CRISPR screen + cryo-EM structure + functional protection assay; multiple orthogonal methods in single study\",\n      \"pmids\": [\"35303428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TFPI serves as a host receptor for multiple TcdB subtypes (TcdB2, 4, 7, 10, 11, 12) from C. difficile that do not recognize Frizzled proteins. A six-residue haplotype within the TcdB receptor-binding region distinguishes TFPI-binding (B4/B7 haplotype) from FZD-binding TcdB variants. Intragenic micro-recombination events drive receptor-specificity switching. TcdB10 recognizes chicken/mouse TFPI but not human TFPI, revealing species selectivity. Introduction of B4/B7-haplotype residues into TcdB1 enables dual recognition of TFPI and FZDs.\",\n      \"method\": \"CRISPR-Cas9 genome-wide screen; receptor binding assays across TcdB subtypes; sequence analysis of 206 TcdB variants; site-directed mutagenesis of receptor-binding residues; species-selectivity binding assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen + mutagenesis + cross-species binding assays; replicates and extends PMID 35303428 finding\",\n      \"pmids\": [\"36351897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A C-terminal peptide (TC24) derived from fish (Cynoglossus semilaevis) TFPI-1 exhibits bactericidal activity against multiple bacterial species (S. aureus, V. vulnificus, M. luteus) by penetrating bacterial cell membranes and inducing degradation of genomic DNA and total RNA. In vivo administration of TC24 reduces pathogen dissemination and viral replication in tongue sole tissues.\",\n      \"method\": \"Antimicrobial assay; membrane integrity assay; intracellular localization by microscopy; genomic DNA/RNA degradation assay; in vivo challenge with bacteria and virus followed by pathogen quantification in tissues\",\n      \"journal\": \"Fish & shellfish immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic assays (membrane disruption, nucleic acid degradation) plus in vivo protection; fish ortholog of TFPI\",\n      \"pmids\": [\"27840169\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TFPI is a multivalent Kunitz-type plasma anticoagulant that directly inhibits factor Xa via its K2 domain, and in a factor Xa-dependent manner forms a quaternary inhibitory complex (TF-FVIIa-FXa-TFPI) to shut down extrinsic pathway initiation, with K1 engaging the FVIIa active site; protein S acts as a cofactor reducing the Ki for FXa inhibition ~10-fold; the TFPIα isoform additionally inhibits prothrombinase through a novel exosite interaction between its basic C-terminus and the factor Va B-domain acidic region; TFPIβ is GPI-anchored to endothelial surfaces; heparin releases TFPI from endothelial stores; TFPI also inhibits MASP-2 of the lectin complement pathway via K2; interacts with angiomotin (AMOT) in vascular smooth muscle cells to modulate YAP/Hippo signaling; and its extracellular domains serve as the colonic crypt receptor for clade 2 C. difficile TcdB toxin variants.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TFPI is a multivalent Kunitz-type serine protease inhibitor that serves as the principal negative regulator of the extrinsic coagulation pathway, functioning at the intersection of hemostasis, complement, vascular biology, and host–pathogen interactions. Its second Kunitz domain (KD2) binds and inhibits factor Xa, and the resulting TFPI–FXa complex then inhibits the TF–FVIIa complex to form a quaternary TF–FVIIa–FXa–TFPI complex with sub-nanomolar affinity, a reaction requiring phospholipids and the FXa Gla domain; protein S acts as a physiological cofactor that stimulates TFPI-mediated FXa inhibition approximately 10-fold, while heparin releases endothelial surface-bound TFPI and synergistically enhances its anticoagulant activity together with antithrombin [PMID:23347185, PMID:20002538, PMID:1346095, PMID:26607136]. Beyond coagulation, TFPI inhibits MASP-2 of the lectin complement pathway via KD2, interacts with angiomotin (AMOT) in vascular smooth muscle cells to modulate Hippo/YAP signaling and suppress proliferation, and functions as a cell-surface receptor exploited by hypervirulent Clostridioides difficile TcdB variants for colonic epithelial entry [PMID:25359215, PMID:27875740, PMID:35303428]. Genetic loss of Tfpi causes embryonic lethal disseminated intravascular coagulation in mice, which is rescued by concomitant PAR4 deficiency, establishing TFPI as essential for restraining thrombin-dependent platelet activation during development [PMID:25954015].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Identifying TFPI's cellular source resolved where the extrinsic pathway inhibitor originates and how it enters the circulation: endothelial cells constitutively produce TFPI, and heparin mobilizes it into plasma.\",\n      \"evidence\": \"Gel filtration of endothelial cell culture supernatant and in vivo heparin injection studies measuring TFPI activity\",\n      \"pmids\": [\"3413731\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of TFPI attachment to the endothelial surface not defined\", \"Identity of heparin-releasable versus circulating TFPI pools not resolved\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstrating that TFPI and heparin act synergistically — and that TFPI depletion converts the heparin dose-response from threshold-dependent to linear — established TFPI as an essential cofactor for heparin's anticoagulant action on the extrinsic pathway.\",\n      \"evidence\": \"PT/APTT assays in TFPI-depleted versus normal plasma reconstituted with recombinant TFPI and various sulfated polysaccharides\",\n      \"pmids\": [\"1346095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether antithrombin is the sole mediator of heparin's synergy with TFPI or whether direct heparin–TFPI binding contributes\", \"Role of different TFPI isoforms not distinguished\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of protein S as a direct TFPI cofactor that stimulates FXa inhibition ~10-fold explained why protein S deficiency causes hypercoagulability beyond its known role with APC, linking two anticoagulant systems.\",\n      \"evidence\": \"Surface plasmon resonance for direct TFPI–protein S binding, thrombin generation assays with protein S immunodepletion, TFPI antigen measurements in protein S-deficient patients\",\n      \"pmids\": [\"20002538\", \"19661488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the TFPI–protein S interaction unknown\", \"Relative contribution of protein S cofactor activity for TFPIα versus TFPIβ not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Domain-resolution reconstitution mapped the complete inhibitory mechanism: KD2 inhibits FXa, the KD3-C-terminus is required for phospholipid-dependent quaternary TF–FVIIa–FXa–TFPI complex formation (Ki <0.15 nM), and protein S stimulates TF–FVIIa inhibition — establishing the molecular logic of TFPI's sequential, FXa-dependent feedback inhibition.\",\n      \"evidence\": \"Chromogenic substrate assays with full-length TFPI and truncated constructs (TFPI1-150, KD1-KD2, KD1) ± TF, phospholipids, protein S, FXa\",\n      \"pmids\": [\"23347185\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the quaternary complex not determined\", \"How FVa-assembled prothrombinase shields FXa from TFPI not structurally resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that TFPI inhibits MASP-2 of the lectin complement pathway via KD2 — without affecting MASP-1 or classical pathway proteases — extended TFPI's function beyond coagulation into innate immune regulation.\",\n      \"evidence\": \"Ex vivo lectin pathway complement assay (C4 deposition), fluid-phase MASP-2 chromogenic assay, domain-specific antibody mapping\",\n      \"pmids\": [\"25359215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological relevance of TFPI–MASP-2 inhibition not tested\", \"Whether TFPI-MASP-2 inhibition occurs at endothelial surfaces or only in fluid phase unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic epistasis showing that Tfpi−/− embryonic lethality (from DIC) is rescued by PAR4 deficiency demonstrated that TFPI is physiologically essential for restraining thrombin-dependent platelet activation during embryonic development.\",\n      \"evidence\": \"Tfpi+/− × Par4−/− crosses in mice with survival analysis, histology, thrombin-antithrombin complex measurement, and injury models\",\n      \"pmids\": [\"25954015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the rescue is complete or only partial in adult thrombotic challenge\", \"Contribution of individual TFPI isoforms to embryonic survival unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of TFPI's interaction with angiomotin (AMOT) and its role in modulating Hippo/YAP signaling in vascular smooth muscle cells revealed a non-hemostatic function: TFPI suppresses VSMC proliferation and migration, and its loss accelerates atherosclerosis.\",\n      \"evidence\": \"Conditional TFPI knockout in VSMCs (ApoE−/− background), mass spectrometry, co-immunoprecipitation, Western blot for AMOT/YAP phosphorylation\",\n      \"pmids\": [\"27875740\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"AMOT–TFPI binding interface not structurally characterized\", \"Whether KD domains or the C-terminus mediates the AMOT interaction unknown\", \"Independent replication of the AMOT–YAP signaling axis in human VSMCs lacking\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genome-wide CRISPR screens and cryo-EM structure determination revealed that TFPI functions as a cell-surface receptor for hypervirulent C. difficile TcdB variants (TcdB2, TcdB4, TcdB7, TcdB10), repurposing TFPI's extracellular domains for pathogen entry into colonic epithelium.\",\n      \"evidence\": \"CRISPR/Cas9 screens, cryo-EM of TcdB4–TFPI complex, mutagenesis of receptor-binding residues, recombinant TFPI protection assays, analysis of 206 TcdB variants\",\n      \"pmids\": [\"35303428\", \"36351897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which TFPI domain contacts TcdB and whether this overlaps with KD2-mediated FXa binding not fully delineated\", \"Whether TFPI-mediated toxin entry occurs through endocytosis or a distinct uptake pathway unclear\", \"In vivo validation that TFPI blockade protects against hypervirulent C. difficile infection not reported\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of the full quaternary TF–FVIIa–FXa–TFPI complex, the structural basis of protein S cofactor activity for TFPI, the isoform-specific contributions of TFPIα versus TFPIβ in different vascular beds, and the physiological significance of TFPI–MASP-2 inhibition in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of the quaternary coagulation complex\", \"Protein S binding site on TFPI not mapped structurally\", \"In vivo role of TFPI-MASP-2 axis untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 7, 8, 13, 15]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [13, 14, 15]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [20, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 5, 9, 10, 20]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [3, 7, 8, 13, 15, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"complexes\": [\n      \"TF-FVIIa-FXa-TFPI quaternary complex\",\n      \"TFPI-protein S complex\"\n    ],\n    \"partners\": [\n      \"F10\",\n      \"F7\",\n      \"F3\",\n      \"PROS1\",\n      \"AMOT\",\n      \"MASP2\",\n      \"SERPINC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"TFPI is a multivalent Kunitz-type serine protease inhibitor that serves as the primary physiological regulator of the extrinsic coagulation pathway by directly inhibiting factor Xa through its Kunitz-2 (K2) domain and, in a factor Xa-dependent manner, forming a quaternary TF–FVIIa–FXa–TFPI complex in which K1 engages the FVIIa active site to shut down tissue factor-initiated coagulation [PMID:3422166, PMID:2927510, PMID:2271516]. Protein S acts as a cofactor that enhances TFPI-mediated FXa inhibition approximately 10-fold, bringing the Ki into the physiologically relevant range, while the TFPIα isoform additionally inhibits prothrombinase through an exosite interaction between its basic C-terminus and the factor Va B-domain acidic region — an activity lost upon thrombin cleavage of FVa — whereas TFPIβ is GPI-anchored to endothelial surfaces where it directly inhibits TF–FVIIa [PMID:16488980, PMID:24127605, PMID:24620349]. Beyond hemostasis, TFPI inhibits MASP-2 of the lectin complement pathway via K2 [PMID:25359215], interacts with angiomotin in vascular smooth muscle cells to modulate YAP/Hippo signaling and suppress atherosclerotic remodeling [PMID:27875740], and functions as the colonic crypt receptor for clade 2 Clostridioides difficile TcdB toxin variants as defined by CRISPR screening and cryo-EM structural analysis [PMID:35303428, PMID:36351897].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Establishing that tissue factor pathway inhibition requires the simultaneous presence of factor VIIa/TF, catalytically active FXa, and the inhibitor resolved the long-standing question of how the extrinsic pathway is downregulated by showing it depends on its own product (FXa) as a cofactor for feedback inhibition.\",\n      \"evidence\": \"Reconstituted activated peptide release assays using purified/depleted plasma components with 3H-FIX substrate\",\n      \"pmids\": [\"3492226\", \"3024756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the inhibitor was not yet determined\", \"Stoichiometry of the quaternary complex was unknown\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Cloning TFPI (LACI) revealed a three-Kunitz-domain architecture and demonstrated that it directly inhibits FXa and forms a quaternary VIIa–TF–Xa–LACI complex requiring the FXa Gla domain, providing the first molecular framework for its dual inhibitory mechanism.\",\n      \"evidence\": \"cDNA cloning and sequencing; in vitro chromogenic substrate assays, nondenaturing PAGE complex detection, Gla-domain-deleted FXa competition\",\n      \"pmids\": [\"2452157\", \"3422166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which Kunitz domain inhibits which protease was unknown\", \"Post-translational processing and isoform diversity were uncharacterized\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Demonstrating that heparin releases TFPI from endothelial cells in a dose-dependent manner identified the vascular endothelium as a physiological reservoir and suggested that part of heparin's clinical anticoagulant effect operates through TFPI mobilization.\",\n      \"evidence\": \"In vivo heparin injection in humans; chromogenic EPI activity assay in plasma; gel filtration of endothelial conditioned medium; polybrene/antibody controls\",\n      \"pmids\": [\"3413731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of endothelial TFPI storage and release was undefined\", \"Relative contributions of heparin-released TFPI vs. antithrombin potentiation were not quantified\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Site-directed mutagenesis mapped K2 as the FXa-inhibitory domain and K1 as the VIIa/TF-inhibitory domain, while K3 had no direct protease-inhibiting function, establishing the domain-function architecture that guided all subsequent TFPI biology.\",\n      \"evidence\": \"Active-site mutagenesis of each Kunitz domain with quantitative FXa and VIIa/TF inhibition assays\",\n      \"pmids\": [\"2927510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Function of K3 and the C-terminal basic region remained unknown\", \"Structural basis of the K1–VIIa and K2–Xa interactions was unresolved\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Reconstitution experiments in TFPI-depleted plasma demonstrated that TFPI synergizes with heparin/sulfated polysaccharides to prolong tissue factor-triggered clotting, quantifying TFPI as a physiologically significant modulator of the anticoagulant effect of heparin therapy.\",\n      \"evidence\": \"APTT and modified PT assays with LACI-depleted plasma reconstituted with purified recombinant LACI; heparin and polysaccharide titrations\",\n      \"pmids\": [\"1346095\", \"2271516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TFPI acts additively or mechanistically synergistically with antithrombin was unclear\", \"In vivo quantitative contribution of TFPI to heparin anticoagulation was not yet established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of protein S as a cofactor that reduces the TFPI–FXa Ki ~10-fold (from 4.4 nM to 0.5 nM) answered the question of how TFPI achieves effective FXa inhibition at its low plasma concentration, revealing a previously unrecognized anticoagulant partnership.\",\n      \"evidence\": \"Purified protein reconstitution with chromogenic substrate assay; kinetic Ki determination; plasma thrombin generation assays\",\n      \"pmids\": [\"16488980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface between protein S and TFPI was not structurally defined\", \"Whether protein S cofactor activity is isoform-specific was unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstration that protein S and TFPI form a stable plasma complex — and that protein S deficiency causes co-depletion of TFPI — established that the hypercoagulable state in protein S deficiency is partly attributable to loss of TFPI function.\",\n      \"evidence\": \"Protein S immunodepletion with TFPI ELISA quantification; surface plasmon resonance binding; calibrated automated thrombography\",\n      \"pmids\": [\"20002538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and domain requirements for the protein S–TFPI complex were not mapped\", \"Clinical impact of co-deficiency versus isolated protein S deficiency was not dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery that TFPIα inhibits prothrombinase through a high-affinity exosite interaction between its basic C-terminus and the FVa B-domain acidic region — lost after thrombin cleaves FVa — revealed an entirely new anticoagulant function beyond TF pathway inhibition, providing a temporal switch that limits early but not propagated coagulation.\",\n      \"evidence\": \"Purified prothrombinase reconstitution; TFPIα vs. TFPIβ comparison; FVa B-domain deletion mutants; thrombin cleavage experiments\",\n      \"pmids\": [\"24127605\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the C-terminus–B-domain interaction was not resolved\", \"Physiological contribution of prothrombinase inhibition versus TF pathway inhibition in vivo was unmeasured\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Systematic domain-deletion kinetics showed that the K3–C-terminal region enhances FVIIa inhibition 7–10-fold and that phospholipids and the FXa Gla domain are essential for quaternary complex assembly, completing the quantitative model of TFPI's multidomain inhibitory mechanism.\",\n      \"evidence\": \"Chromogenic FVIIa activity assays with truncated TFPI constructs; relipidated and soluble TF; protein S titrations; quantitative Ki analysis\",\n      \"pmids\": [\"23347185\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of the full quaternary complex was not available\", \"How membrane composition modulates complex assembly in vivo was unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing that TFPI selectively inhibits MASP-2 (but not MASP-1, C1s, or C1r) via K2 expanded TFPI's functional repertoire beyond coagulation to regulation of the lectin complement pathway, suggesting a role at the coagulation–innate immunity interface.\",\n      \"evidence\": \"Lectin pathway C4 deposition assay on mannan-coated plates; fluid-phase MASP-2 chromogenic assay; domain-mapping with anti-K2 monoclonal antibodies\",\n      \"pmids\": [\"25359215\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo significance of TFPI–MASP-2 inhibition for complement regulation was not demonstrated\", \"Whether physiological TFPI concentrations are sufficient to modulate lectin pathway in plasma was untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic epistasis showing that PAR4 deficiency partially rescues Tfpi-null embryonic lethality demonstrated that TFPI's physiological role extends to modulating thrombin-dependent platelet activation in vivo, and that loss of TFPI causes lethal disseminated intravascular coagulation through uncontrolled thrombin signaling.\",\n      \"evidence\": \"Tfpi−/−:Par4−/− double knockout mouse crosses; survival analysis; fibrin immunohistochemistry; thrombin-antithrombin complex measurement; injury models\",\n      \"pmids\": [\"25954015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TFPIα prothrombinase inhibition specifically mediates the embryonic rescue was not dissected\", \"Human genetic correlates of TFPI deficiency remain poorly defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Conditional TFPI knockout in vascular smooth muscle cells accelerated atherosclerosis and identified angiomotin (AMOT) as a TFPI-interacting partner that modulates YAP/Hippo signaling, revealing a non-hemostatic function of TFPI in vascular remodeling.\",\n      \"evidence\": \"Conditional knockout mouse (Tfpi1fl/fl/Sma-Cre+ApoE−/−); mass spectrometry; Co-IP of AMOT; Western blot for YAP phosphorylation; qPCR for SLUG/CTGF\",\n      \"pmids\": [\"27875740\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interface between TFPI and AMOT was not mapped\", \"Whether AMOT interaction is isoform-specific was not determined\", \"Single lab without independent replication\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of TFPI as the colonic crypt receptor for clade 2 C. difficile TcdB variants — supported by CRISPR screening, cryo-EM structure, and functional protection assays — established an unexpected role for TFPI's extracellular domains in toxin entry and defined a new therapeutic target for hypervirulent C. difficile infection.\",\n      \"evidence\": \"Genome-wide CRISPR/Cas9 screen; cryo-EM of TcdB4–TFPI complex; recombinant TFPI protection of colonic epithelium; cross-subtype binding and mutagenesis across 206 TcdB variants\",\n      \"pmids\": [\"35303428\", \"36351897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TFPI-mediated toxin entry occurs via endocytosis of the GPI-anchored TFPIβ isoform or free TFPIα was not resolved\", \"Species selectivity determinants on TFPI itself were not fully mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic-resolution structure of the full quaternary TF–FVIIa–FXa–TFPI complex, the structural basis of the TFPIα C-terminus interaction with the FVa B-domain, in vivo quantification of the relative contributions of TFPIα prothrombinase inhibition versus TF pathway inhibition, and the physiological significance of TFPI–MASP-2 inhibition in complement regulation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Full quaternary complex structure unavailable\", \"In vivo dissection of isoform-specific anticoagulant contributions incomplete\", \"Physiological relevance of complement pathway inhibition by TFPI untested in animal models\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 4, 8, 13, 15, 16, 18]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [4, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 5, 6, 9, 13, 14]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [17, 20]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 2, 4, 7, 8, 11, 13, 15, 16, 17, 18, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"complexes\": [\n      \"TF-FVIIa-FXa-TFPI quaternary complex\",\n      \"TFPI-protein S complex\",\n      \"FXa-FVa prothrombinase (TFPIα target)\"\n    ],\n    \"partners\": [\n      \"F10\",\n      \"F7\",\n      \"F3\",\n      \"PROS1\",\n      \"F5\",\n      \"MASP2\",\n      \"AMOT\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}